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ABSTRACT 
 
Malnutrition among individuals with head and neck cancer (HNC) is of 
particular concern, with up to 40% - 57% with a compromised nutritional status 
even before beginning their treatment. Within the US, the prevalence of 
malnutrition has not been well-documented due to a lack of consensus on its 
definition and diagnosing markers. Therefore, the primary aim of this prospective 
natural history pilot study was to estimate the prevalence of malnutrition among 
individuals with HNC (n = 19) during and up to 3 months after treatment using the 
new Consensus malnutrition definition. The scored Patient-Generated Subjective 
Global Assessment (PG-SGA) was used as the reference standard to evaluate 
the sensitivity and specificity of the Consensus framework in defining 
malnutrition. Another aim of this research was to investigate the utility of raw 
bioimpedance parameters such as 50 kHz phase angle (PA) and 200 kHz/5 kHz 
impedance ratio (IR) to identify individuals with malnutrition, and to evaluate how 
bioimpedance markers relate to functional status outcomes. Finally, this research 
also assessed how malnutrition relates to quality of life (QoL) and self-efficacy 
perceptions among individuals with HNC. 
Results indicate that individuals with HNC are malnourished even before 
treatment initiation. Using the Consensus framework, 67% of our participants 
were malnourished before treatment; and the prevalence of malnutrition 
consistently increased during treatment and the post-treatment period. When 
compared to our reference standard PG-SGA, the Consensus criteria identified 
malnutrition with overall good sensitivity (95%) and specificity (43%). 
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Bioimpedance markers PA and IR were useful in identifying individuals who were 
at increased risk for malnutrition and/or impaired functional status. From a 
psychosocial perspective, compared with well-nourished participants, 
malnourished individuals scored significantly lower in the global QoL and 
cognitive function scales and significantly higher in the disease- and treatment-
related symptom scales and items. 
In the future, if clinicians are trained to assess malnutrition diagnostic 
markers before individuals with cancer undergo aggressive treatments, nutritional 
interventions could be initiated at an earlier time and loss in weight and/or lean 
tissue can be prevented. Early detection of malnutrition could also help with 
patient-specific intervention strategies aimed to improve overall health-related 
QoL outcomes. 
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Malnutrition is commonly identified by unintended loss of body weight and 
has been associated with increased morbidity such as impaired wound healing, 
increased post-operative complications, and reduced quality of life. Malnutrition 
among individuals with head and neck cancer (HNC) is of particular concern, and 
depending on the parameters used for its identification, it is estimated that 50 -
70% are malnourished and 25% - 57% have impaired nutrition status at the time 
of diagnosis.1 Poor nutrition may result in treatment delays and/or interruptions 
and increased hospital admissions, which further increases costs and 
compromises the quality of care to the patient.2,3 
Within the US, there is a paucity of data regarding the effect of nutritional 
care during the course of HNC treatment, and the lack of a consensus definition 
of malnutrition has made early identification and diagnosis of malnutrition a 
challenge. Recently, the Academy of Nutrition and Dietetics in conjunction with 
the American Society for Parenteral and Enteral Nutrition have published a joint 
consensus regarding identification of adult malnutrition.3 If malnutrition is 
appropriately diagnosed at an earlier stage of treatment, the clinical team can 
take the necessary steps to address the condition early, which could positively 
influence patient health, decrease length of stay, and reduce costs. Therefore, 
the primary aim in conducting this prospective pilot study was to estimate 
the prevalence of malnutrition among individuals with HNC during and up 
to 3 months after treatment using the new consensus definition. 
Routine assessment of body composition is important for identification of 
individuals with HNC who might be at risk for malnutrition due to progressive 
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losses of lean muscle mass.  Lean tissue depletion has been associated with 
reduced functional status, higher infections, and lengthier stay in hospital among 
those who are malnourished.4–7 Changes in body composition have not been 
sufficiently investigated in the HNC setting during and after treatment.  
Additionally, without body composition assessment, it is not possible to discern 
whether any gain in body weight is due to a gain in muscle mass or is simply due 
to fat accumulation or fluid retention. Simple anthropometric measures such as 
body weight and body mass index are not sensitive to changes in body 
composition.7,8 Clearly, the diagnosis of malnutrition may be improved by 
incorporating feasible body composition measures such as those provided by 
bioimpedance devices that can be used to assess changes in lean muscle mass 
over time. Therefore, the second aim of this research was to investigate 
whether clinicians can potentially use raw bioimpedance parameters such 
as 50 kHz phase angle and 200 kHz/5 kHz impedance ratio to identify 
individuals with malnutrition, and to evaluate how bioimpedance markers 
relate to functional status outcomes. 
HNC-related symptoms and intensive treatment regimens can negatively 
affect the basic functions of living such as speech, respiration, hearing, eating, 
chewing, and swallowing.8,9 Health-related quality of life is therefore an important 
parameter to assess among individuals with HNC at various time points during 
and after treatment. Cancer diagnosis and treatment can also negatively affect 
individuals’ self-efficacy to cope with illness-related stress and threaten their 
psychosocial well-being and quality of life.10 However, limited research has 
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investigated the relation between malnutrition and quality of life or coping self-
efficacy in the HNC setting. Therefore, the third aim for this research was to 
assess how malnutrition relates to quality of life and self-efficacy 
perceptions among individuals with HNC.  
In the following chapters, this dissertation addresses these three aims. 
Chapter 2 provides a literature review on the background information relevant to 
these aims; part I addresses nutrition-related and psychosocial aspects of HNC, 
and part II reviews bioimpedance techniques for bed-side assessment. Chapter 3 
addresses the first 2 aims of the study, identifying the prevalence of malnutrition 
among individuals with HNC and investigating the utility of bioimpedance 
parameters for the assessment of malnutrition. Chapter 4 addresses the third 
aim, evaluating whether quality of life and coping self-efficacy relate to 
malnutrition and further investigates the association between the quality of life 
and functional status outcomes. Lastly, Chapter 5 provides overall conclusions 
and suggestions for future directions. 
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Head and Neck Cancer (HNC) Malnutrition: An Overview 
Malnutrition is highly prevalent among individuals with HNC, with up to 
40% - 57% having a compromised nutritional status even before beginning their 
treatment.1,11 Previously, HNC malnutrition has been associated with poor 
survival outcomes and increased morbidity including post-surgical complications, 
risk of infections, impaired wound healing and recovery, declining quality of life 
(QoL) and functional status, and poor disease prognosis.1,8,11–15 Lethargy, loss of 
appetite, anxiety, and depression, as well as surgery-, chemotherapy-, and 
radiotherapy-related side-effects (e.g., difficulty chewing, pain while swallowing, 
mouth sores) are some of the key factors contributing to inadequate dietary 
intake, resulting in unintended weight loss and loss of fat and muscle mass.1,8 
From the health care perspective, malnutrition is associated with frequent 
treatment interruptions and increased hospital readmissions and length of stay, 
further adding to costs related to patient care.2,3 
Malnutrition: An Etiology-Based Definition is Needed 
Although malnutrition in the United States (US) has been recognized as a 
significant clinical problem, a lack of standardization in defining, diagnosing, and 
documenting malnutrition has made addressing this issue a continuous challenge 
for clinicians.3,16 The 2012 Academy of Nutrition and Dietetics and American 
Society for Parenteral and Enteral Nutrition Consensus Statement on adult 
malnutrition has noted the necessity for a uniform definition, and has suggested 
the use of two or more of the following six markers for diagnosis: insufficient 
energy intake, weight loss, loss of muscle mass, loss of subcutaneous fat, 
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localized or general fluid accumulation, and diminished functional status as 
measured by hand grip strength.3 Additionally, it is important to screen all 
patients in order to identify those at risk for malnutrition through the 
administration of appropriate screening tools. Although nutrition screening is 
used to identify risk of malnutrition based on readily accessible information upon 
admission, nutrition assessment involves more in-depth evaluation to diagnose 
malnutrition utilizing the aforementioned parameters.17 Early detection of 
malnutrition through timely screening, and subsequent assessment and 
intervention has been shown to improve QoL and tolerance to treatment.16,17 
Nevertheless, the efficacy of early nutritional screening in identifying those at risk 
for malnutrition has not yet been examined among individuals with HNC. 
In inpatient clinical facilities, the Joint Commission mandates that all newly 
admitted patients undergo screening for malnutrition within 24 hours of 
admission, and then patients that are identified as high risk undergo a complete 
nutrition assessment by a Registered Dietitian Nutritionist within a time-frame 
specified by the individual facility.17 While outpatient clinical facilities are not 
mandated to routinely screen individuals with HNC for the risk of malnutrition, in 
those that do, there is significant variation in the screening parameters used. 
Similarly, clinicians may use different assessment parameters to diagnose 
malnutrition, which heretofore has not had a clear consensus-driven definition; 
this has resulted in a wide range of reported HNC malnutrition prevalence 
(ranging from 19% to 70%).1,3,16 Therefore, an important first step to more 
accurately estimate the prevalence of malnutrition among individuals with HNC is 
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to implement the malnutrition definition and guidelines from the recent 
Consensus Statement. In addition, the efficacy of incorporating screening tools to 
identify those at-risk for malnutrition (especially during the pre-treatment period) 
at outpatient clinical facilities also needs to be examined. 
Malnutrition and Functional Status Markers 
Hand grip Strength 
Hand grip strength is a simple, non-invasive marker of muscle strength 
and functional status that has been used among the hospitalized elderly, general 
surgery, and among individuals with HNC.8,18 Impaired grip strength correlates 
with decreased muscle function18 and losses of total body protein,19 and is 
associated with immediate postoperative complications and poor nutritional 
status among individuals with cancer.18,20,21 Additionally, chronic inflammation, 
skeletal muscle catabolism, and poor nutritional intake and sedentary behavior 
during HNC treatment often results in loss of protein and lean muscle mass 
stores.8,20 Although research has shown that disease-related malnutrition results 
in impaired muscle function and strength, such data are limited in individuals with 
HNC, especially during the course of their treatment. 
Five-times-sit-to-stand-test 
Five-times-sit-to-stand-test (FTSST) is another measure for assessing 
functional status, and it involves recording the quickest time required by a 
participant to rise and sit down five times from a chair.22 Yielding high reliability 
and validity, the FTSST has been used to assess lower extremity muscle 
strength and balancing function among the frail elderly, and individuals with 
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Parkinson’s disease, arthritis, stroke, prostate cancer, cerebral palsy, spinal cord 
injury, and chronic obstructive pulmonary disease.22–28 Higher FTSST time is 
associated with impaired muscle function and strength, poor balance, and a 
higher risk for falls among the elderly.22,24,27 To date, the reliability of FTSST has 
not been tested among individuals with HNC who usually undergo losses in 
muscle mass and strength during treatment. Such data will provide valuable 
information for clinicians who could easily incorporate a feasible and quick to 
administer measure such as the FTSST to assess functional status and muscle 
function during various phases in treatment. 
Psychosocial Measures 
Quality of Life (QoL) 
Head and neck cancer-related symptoms and intensive treatment 
regimens can negatively affect the basic functions of living such as speech, 
respiration, hearing, eating, chewing, and swallowing.8,9 Among individuals with 
advanced disease, issues with facial disfigurement, general appearance, and 
communication affect social interaction and activities of daily living, which may 
lead to isolation and depressive symptoms, also influencing adherence to 
treatment and recovery.9,29–31 Health-related quality of life is therefore an 
important parameter to assess among individuals with HNC at various time 
points during and after treatment. Such data provide valuable information about 
treatment-related symptoms, and physical, psychological, and social functioning, 
and further help to identify individuals in need of clinical and therapeutic 
interventions.8,30  
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Although prospective studies have assessed QoL among individuals with 
HNC during various treatment and post-treatment time points,9,29–31 limited data 
are available on how QoL relates to malnutrition and associated symptoms. HNC 
research investigating the effect of nutritional symptoms (including malnutrition) 
on QOL has mostly been conducted elsewhere (Italy, The Netherlands, 
Portugal),32–35 and such data are lacking in the US. 
Coping Self-efficacy 
Self-efficacy theory suggests that the greater a person’s self-confidence to 
execute a course of action (e.g., coping with cancer pain), the higher the 
probability that the desired goal (e.g., to improve QoL) will be attained.36 Coping 
self-efficacy is a form of self-efficacy that refers to people’s beliefs in their ability 
to negotiate particular stressors or obstacles.37 Such beliefs affect how people 
perceive and react to adverse life events and conditions, and favorable coping 
self-efficacy perceptions help people to draw effectively on social support and 
persist at problem-solving when faced with difficult situations.  
Cancer diagnosis and treatment can negatively affect patients’ self-
efficacy to cope with illness-related stress and threaten their psychosocial well-
being and QoL.10 Previous oncology research has indicated that individuals with 
higher self-efficacy report better health-related QoL, may live longer, feel less 
depressed, participate in treatment decision making, and exhibit  fewer illness 
related symptoms compared to those who are less efficacious in coping.10,37–40 
Therefore, perceptions regarding self-efficacy are important to clinical knowledge 
so that individuals’ cancer-coping strengths and weaknesses may be identified, 
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and possible psychosocial interventions may be administered in a timely way0. 
Research investigating self-efficacy perceptions among individuals with HNC is 
particularly limited, and the current study will delineate the influence of this 
important psychosocial construct among this patient population. 
Malnutrition and Assessment of Lean Tissue 
The loss of muscle mass is a defining characteristic for malnutrition and 
sarcopenia.3,41 A low skeletal muscle mass has also been associated with 
treatment-related adverse events among individuals with breast, lung, and renal 
cancer.42–45 Therefore, there has been a significant interest in the estimation of 
lean tissue in the clinical setting. However, limited methods are available for this 
purpose. Dual-energy X-ray absorptiometry (DXA) measures fat and lean soft 
tissue mass through X-ray attenuation.46 DXA scanners are used in a variety of 
settings including exercise and radiology labs,46 and as an assessment method, 
DXA is precise, safe (although it involves minor exposure to radiation), quick to 
administer, and requires moderate cooperation from the participant.47,48However, 
DXA scanners are relatively expensive, non-portable, and require trained 
technicians for their operation and maintenance.49–51 Therefore DXA appears to 
be a less feasible and/or practical option for lean tissue assessment in the HNC 
population.  
Another method used in the assessment of lean tissue is computerized 
tomography (CT) scanning.47 Previously, CT scanning has been reported to be a 
precise, valid, and accurate method to assess body composition.44,46,52,53 
Although CT scanning is regarded as an accurate measure of body composition 
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at the tissue-organ level, this method is expensive and requires skilled 
technicians for operation.47,54 Additionally, CT scanning is time consuming and 
exposes individuals to a relatively higher dose of radiation making it unsafe for 
repeated measurements.47 CT scanning is thus typically not used clinically as a 
body composition method. However, many cancer patients (particularly those 
with gastrointestinal and abdominal cancers) undergo CT scanning for diagnostic 
purposes and thus, scans can be utilized to assess lean tissue. For example, CT 
scans were used to assess skeletal muscle mass among individuals with 
advanced gastrointestinal and lung cancers, and a substantial number of 
individuals with obesity were found to meet the criteria for sarcopenia.44,53  
Given the challenges with CT and DXA, there is a growing interest in the 
use of bioimpedance devices for the assessment of lean tissue at the bed-
side.46,55 Bioimpedance techniques are non-invasive, portable, require little 
training for operation, and are relatively lower cost alternatives to DXA and CT 
scanning.49,54,56,57 A thorough review of the various bioimpedance techniques and 
their clinical utility to provide whole body estimates of lean tissue for bed-side 
nutritional assessment is discussed in the following section. 
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Overview 
The loss of muscle mass is a defining characteristic of malnutrition and 
there has been an ongoing interest in the assessment of lean tissue at the bed-
side. Globally, bioimpedance techniques have been widely appreciated for their 
non-invasiveness, safety, ease of use, portability, and relatively low cost 
compared to other clinically available methods. In this brief update, we review the 
three primary types of commercially available bioimpedance devices (single- and 
multiple-frequency and spectroscopy) and differentiate the underlying theory and 
current applications of each. We also address limitations and potential 
opportunities for using these devices at the bed-side for clinical assessment. 
Mixed reports in the validation literature for all bioimpedance approaches have 
raised questions about absolute accuracy to estimate whole body composition in 
clinical populations, particularly those with abnormal fluid status and/or body 
geometry in whom underlying method assumptions may be violated. Careful 
selection of equations can improve whole body estimates by single- and multiple-
frequency techniques, however, not all devices will allow for this approach. 
Research is increasing on the use of bioimpedance variables including phase 
angle and impedance ratio as potential markers of nutritional status and/or 
clinical outcomes; consensus on reference cut-points for interpreting these 
markers have yet to be established. Novel developments in the bioimpedance 
spectroscopy approach are allowing for improved fluid management in 
individuals on dialysis; these have implications for the clinical management of 
other conditions associated with fluid overload, and may also prove to provide 
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enhanced whole body estimates of lean tissue through new modeling 
procedures. 
Introduction 
The new Consensus malnutrition framework3 features the loss of muscle 
mass as one of the key characteristics defining malnutrition. The loss of muscle 
mass is also a key characteristic of sarcopenia, which is a core defining 
characteristic of cachexia.58 From a therapeutic standpoint, lean tissue is an 
important concept for appropriate drug dosing, given the risk of toxicity with 
certain drug therapies in individuals with lean tissue depletion.42,43,45 
Furthermore, the current American Society of Parenteral and Enteral Nutrition 
critical care guidelines recommend that protein delivery in individuals with 
extreme obesity should be based on ideal body weight;59 but it is likely that a 
more effective strategy would be to dose protein on the basis of lean tissue given 
what we know about the relationship between the two.60–63 For these reasons, 
there has been ongoing interest in the assessment of body composition (and in 
particular lean tissue) at the bed-side. Globally, bioimpedance techniques have 
been widely appreciated for their non-invasiveness, safety, ease of use, 
portability, and relatively low cost compared to other clinically available methods 
(e.g. dual-energy X-ray absorptiometry [DXA]);56,64 and various applications of 
bioimpedance across the lifespan were presented in a recent supplement of the 
European Journal of Clinical Nutrition.65 There are three primary categories of 
devices available today, including single-frequency, multiple-frequency, and 
spectroscopy. Although single-frequency devices were the first to be made 
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commercially available and are the most abundant in the market place, multiple-
frequency and spectroscopy devices are becoming more readily available. 
Thorough reviews of the validation literature for whole body composition 
estimates have been published previously.55,66 Although many available 
bioimpedance devices have been shown to be relatively valid for estimating fat-
free mass (FFM) and other body composition compartments in healthy normal 
weight individuals, studies in various clinical populations are much less abundant 
and tend to yield mixed results regardless of approach. All bioimpedance 
approaches have been shown to be largely erroneous for whole body 
composition estimates in individuals with obesity.67–70 Although refinements in 
bioimpedance techniques have led to important advancements in the 
management of individuals on dialysis, the clinical applications for whole body 
lean tissue assessment require additional development. Validation studies in 
clinical populations have typically reported good mean-level agreement between 
bioimpedance and reference methods based on correlation and paired t-test 
statistics, but poor accuracy at the individual level (i.e. wide limits of agreement 
by Bland-Altman analysis) raising doubts about the capacity of bioimpedance 
techniques to accurately quantify whole body compartments. It should be noted 
that each reference method has a certain amount of inherent error, and it can be 
argued that the aforementioned statistical techniques utilized to prove validity do 
not effectively take into account the errors associated with the reference.71 
Furthermore, prediction equations are scaled to a particular reference method 
and when evaluated against a different reference method can produce error. For 
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example, a bioimpedance equation that may have been developed for FFM from 
DXA may produce substantial scaling errors when compared against total body 
water (TBW) measures generated by deuterium dilution in a different study. 
Although in many cases the errors in estimates generated from bioimpedance 
techniques at the individual level probably are truly significant, it is certainly 
possible that at least some of the time bioimpedance techniques have been 
unfairly judged to be erroneous due to these limitations inherent to body 
composition validation studies. 
Nevertheless, there remains significant global interest in the applications of 
bioimpedance techniques for bed-side assessment of nutritional status either 
through the evaluation and monitoring of whole body lean tissue, or through the 
interpretation of some bioimpedance derived variable independent of whole body 
mass or volume. Indeed, given the difficulties associated with the validation of 
bioimpedance techniques, there is growing interest in new applications of 
bioimpedance for the clinical setting that go beyond quantifying whole body 
composition. There are also new developments in the field for whole body fluid 
volume management in dialysis that hold promise for improving the capacity to 
estimate whole body lean tissue. In this brief update, we review the three primary 
types of commercially available bioimpedance devices and differentiate the 
underlying theory and current applications of each. We also address limitations 
and potential opportunities for using these devices at the bed-side for clinical 
assessment. 
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General Principles of Bioimpedance 
The three general categories of bioimpedance devices available 
commercially include single-frequency, multiple-frequency, and spectroscopy. 
Regardless of the device, bioimpedance involves the administration of a weak, 
alternating electrical current at one or more radiofrequencies through leads 
attached to surface electrodes in order to characterize the conductive and non-
conductive tissue and fluid components of the body.56,72 The applied current 
flows at various rates depending on the composition of the body, and is well 
conducted by water and electrolyte-rich tissues such as blood and muscle, and is 
poorly conducted by fat, bone, and air-filled spaces.64,72,73 The voltage drop of 
the current as it passes through the body is detected through the current sensing 
electrodes and the impedance data are recorded by the bioimpedance device. 
Bioimpedance measurements are typically taken in the supine position 
following standardized protocol.55,66,73  Electrodes can be attached to the body in 
several different arrangements. The most common approach for generating 
whole body composition estimates is the standard tetrapolar arrangement (also 
termed wrist-ankle), which involves the placement of two electrodes on the hand 
(one on the bony protuberance that forms the wrist, i.e. between the styloid 
processes of the ulna and radius, and the other just behind the meta-carpals), 
and two electrodes on the foot (one on the ankle placed midline between the 
medial and lateral malleoli, and the other just behind the metatarsals). A less 
common option utilized by select devices (e.g. the InBody segmental multiple-
frequency devices) involves the placement of eight electrodes in a tetrapolar 
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arrangement on both hands and both feet. Segmental approaches require the 
placement of electrodes in various arrangements depending on the limb or 
segment to be measured.56,72 
Several excellent reviews provide a comprehensive discussion of 
bioimpedance and the underlying assumptions to available technologies.56,64,72 
However, it is useful to review the core general concepts here. In brief, 
impedance (Z) is the frequency-dependent opposition by the conductor (i.e. the 
body) to the flow of electric current.74,75 Geometrically, impedance is the vector 
composed of two frequency-dependent parameters – resistance (R) and 
reactance (Xc).72,75 Resistance is the opposition to the flow of current when 
passing through the body.72,75 Reactance is the delay in conduction caused by 
cell membranes, tissue interfaces, and non-ionic substances.64,72,73,75 
Capacitance is a function of reactance that arises when cell membranes store a 
portion of the current for a brief time.56This temporary storage of charge creates 
a phase shift or phase angle (PA), quantified as the ratio of the arc tangent of 
reactance to resistance (arc tangent [Xc/R] × [180°/π], expressed in degrees).64 
At very low (or theoretically approaching zero) frequencies, virtually no 
conduction occurs because a higher cell membrane capacitance permits the 
current to only pass through (and therefore quantify) the extracellular water 
(ECW).66,72 At very high (or theoretically approaching infinity) frequencies, total 
conduction occurs through cell membranes, thus allowing for the quantification of 
TBW.66,72 The difference between the TBW and ECW further determines the 
intracellular water (ICW) volume which can theoretically be used to estimate 
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body cell mass (BCM) based on the assumption that cells are comprised of 70% 
water.76 Therefore, the potential applications available depend on the nature of 
the device at hand, including the number and range of frequencies, software 
capacity, quality of circuit board, and other factors. It is useful to consider the 
general framework, underlying assumptions, and strengths and limitations for 
each of the three general approaches for estimating whole body fluid volumes 
and lean and fat tissue masses.  
Bioimpedance for Estimating Whole Body Composition 
Single-Frequency Bioelectrical Impedance Analysis (SF-BIA) 
SF-BIA using a 50 kHz single-frequency device and wrist-ankle tetrapolar 
electrode placement is the most widely utilized bioimpedance approach to 
estimate whole body composition (see Table 1). Most typically, impedance data 
measured at 50 kHz is used to estimate various body compartments through 
application to regression-derived equations previously derived from reference 
data. For example, an equation for predicting TBW would typically be developed 
by measuring TBW using deuterium dilution as the reference method in a 
homogeneous sample from a study population. Bioimpedance data obtained 
from the study sample would then be regressed against TBW reference 
measures in order to develop an equation that can be used to predict TBW from 
bioimpedance data. The new equation must then be cross-validated in a 
separate independent sample of individuals with similar characteristics. Once 
TBW is predicted from SF-BIA generated impedance data applied to such an 
equation, then fat-free mass (FFM) can be derived through the assumption that 
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FFM is constantly hydrated at 73.2%. By this method, fat mass (FM) can then be 
derived through subtraction of FFM from body weight. Thus, it can be 
appreciated that SF-BIA inherently is based upon the two- component model of 
body composition (FM + FFM = Body weight). Alternatively, regression equations 
have been developed based on other appropriate reference methods for directly 
predicting FM, FFM, and other compartments from 50 kHz data; these have been 
well reviewed by Kyle et al.56 Ideally, an equation that is appropriately matched to 
the characteristics of an individual should be chosen to provide optimal body 
composition estimates. However, in the clinical setting there are significant 
barriers to this approach and underlying assumptions to SF-BIA are frequently 
violated. 
First and foremost, the SF-BIA approach relies on an assumption that the 
body is a uniform conductor with constant geometry and composition, and 
resistance (R, ohms) is directly related to the product of specific resistivity (ρ, 
ohm-cm) and conductor length (L, cm), and indirectly related to conductor cross-
sectional area (A, cm2), such that R = ρ (L/A).56,64,72 Rearranging these variables 
allows for the prediction of volume from what has been termed the impedance 
quotient (L2/R) or which is essentially Height2/R (Ht2/R), with an appropriate 
adjustment factor (ρ) which accounts for the lack of uniformity in the conductivity 
of the body. In this way, impedance data can be used to predict the volume (V, 
cm3) of TBW as follows: V = ρ (Ht2/R), also referred to as the ‘volume conductor 
model’.56,64 
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The presumption underlying the whole body SF-BIA approach that the 
human body is a single, symmetrical cylinder with homogenous composition and 
uniform cross-sectional area is not physiologically accurate, as the body can be 
better described by having 5 distinct cylinders (2 arms, 1 trunk, and 2 legs).73,77 
Furthermore, the SF-BIA approach is based on the assumptions that the intra- to 
extracellular water ratio remains constant, and specific resistivity (ρ) is constant 
across all tissues of the body so that the bioelectrical current is conducted 
uniformly.73 However,  is related to factors such as electrolyte concentration 
(inverse relation) and temperature (direct relation),66,73,74 and the distribution of 
fluid between the intra- and extracellular compartments (and consequently the 
electrical properties) of various tissues varies with disease state and nutritional 
status.55 These factors, and the fact that SF-BIA relies solely on the utility of just 
one frequency makes it highly improbable that it can accurately differentiate 
between intra- and extracellular water based on static assumptions; the 
validation literature bears that out.55,73,78 Indeed, clinicians should be wary of 
reports generated by SF-BIA devices in their patients that provide values for 
intra- and extracellular water, BCM, and even bone mass, as they are highly 
questionable. 
Even the generation of TBW by SF-BIA in clinical populations is potentially 
erroneous due to the assumption that 50 kHz is a high enough frequency to 
overcome membrane capacitance to completely quantify both intra- and 
extracellular water. Studies have demonstrated that in certain disease states, 
much higher frequencies are required in order to fully quantify TBW.79,80 At 
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50kHz frequency, the method is actually measuring the weighted sum of ECW 
and ICW resistivities, and not TBW – therefore it estimates TBW without 
distinguishing between or measuring the individual ECW and ICW volumes.56,73 
In addition, FFM is typically derived from TBW following the assumption that FFM 
is constantly hydrated at 73.2%;77 the hydration of FFM has been demonstrated 
to be significantly higher in individuals with obesity81,82 and fluid overload.83,84 
Indeed, predictions of FFM have been reported to be overestimated in cardiac 
and renal settings, where ECW volume expansion is common.55,73 This has also 
been shown among advanced lung and gastrointestinal cancer patients, where 
FFM was overestimated with wide limits of agreement (1.88±7.66 kg) between a 
SF-BIA device (TBF-300A, Tanita) and DXA (Lunar Prodigy Advance, GE 
Healthcare).48 
Finally, it is important to remember that the SF-BIA approach generates 
whole body volumes and masses by using statistically-derived, population-
specific equations (typically height-, weight-, age-, gender-, and ethnicity-specific) 
that have mostly been validated among healthy and normal-weight individuals 
under highly controlled conditions.55,56 Obtaining optimal results for whole body 
compartments even in healthy people depends on the selection of an appropriate 
prediction equation. In reality, many devices do not specify the equation 
programmed into their software, considering that information to be proprietary, 
and clinicians rarely have the time or inclination to search the literature to find an 
equation appropriate to the individual being measured. Furthermore, some 
devices do not provide the raw impedance data (i.e. resistance, reactance, 
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impedance, phase angle), thus making it impossible to recalculate body 
composition compartments using an appropriate equation. This critique can also 
be made of many multiple-frequency devices. 
There is a growing body of literature investigating the utility of 50 kHz 
derived bioimpedance data to either enhance nutrition assessment or 
independently predict nutritional status and/or clinical outcomes, without relying 
on predictions of whole body volumes or masses.46,85 Specifically, phase angle 
can be compared to population-specific reference values.86–89 50 kHz data can 
also be used to generate fat-free mass index (FFMI), a height corrected index of 
FFM that can be calculated by a standardized equation and compared to 
reference data.90 Another parameter that can be generated from 50 kHz data is 
derived from a graphical procedure called bioelectrical impedance vector 
analysis (BIVA); this method involves the plotting of resistance and reactance 
standardized for height to create a vector that can then be compared to gender- 
and race-specific reference values from healthy population samples.91,92 The use 
of BIA data in this way is theoretically advantageous in situations where 
bioimpedance assumptions are not valid to estimate body composition. The BIVA 
method presents some logistical challenges for clinical application given that few 
devices are programmed with software appropriate to calculate it. BIVA has been 
reviewed elsewhere;55,85 PA and FFMI will be further discussed in a subsequent 
section. 
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Multiple-Frequency BIA (MF-BIA) 
Similar to SF-BIA, the most commonly applied MF-BIA approach for the 
determination of whole body masses and volumes involves the measurement of 
impedance using the wrist-ankle tetrapolar electrode placement, and then 
applying the data obtained at two or more frequencies to regression-derived 
population-specific prediction equations.56,66 Although a bioimpedance 
spectroscopy (BIS) device can be used to generate data that can be applied to 
MF-BIA prediction equations, it is most common to take this approach using an 
actual MF-BIA device. Typically, MF-BIA devices apply the current at one very 
low frequency (e.g. 5 kHz) and several higher frequencies (e.g. 50, 100, 200, 500 
kHz; see Table 1). Thus, theoretically, MF-BIA is able to differentiate between the 
ECW and ICW compartments, as at lower frequencies, impedance to current flow 
determines the ECW, while at higher frequencies the impedance quantifies the 
TBW; ICW can be derived by subtracting ECW from TBW.56,73 This represents 
one potential advantage of MF-BIA over SF-BIA approaches, although the 
efficacy of selecting one specific high frequency to completely quantify TBW 
across all clinical populations is somewhat questionable, particularly in those with 
fluid overload. A number of validation studies of various equations to predict 
whole body composition in healthy and clinical populations can be found in the 
literature and have been reviewed previously.56 The same challenges described 
for the SF-BIA validation literature are evident in the MF-BIA validation literature, 
typically with good population-level agreement but large individual variability 
being reported. Furthermore, with the exception of the assumption regarding the 
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static ratio of intra- to extracellular water, the same underlying assumptions 
inherent to SF-BIA hold true for MF-BIA, thus potentially limiting its applications 
for whole body composition assessments in clinical populations.46 
Although it was first explored using a 50 kHz SF-BIA device,93 there has 
been increasing interest in the use of segmental measurements with MF-BIA to 
potentially produce more accurate whole body composition estimates.94 Unlike 
whole body wrist-ankle bioimpedance measurements that relate Ht2/R to 
estimate TBW based on the volume conductor model (as discussed previously), 
segmental BIA recognizes the body as having 5 distinct cylinders with different 
resistivities over which impedances are measured separately.95 One of the 
criticisms that can be made of whole body wrist-ankle measurements is that the 
trunk contributes very little to whole body resistance (~10%) but comprises a 
substantial conductor volume (~50%).56,72,96 Further, the assumption is made that 
any changes in fluid volume or adiposity within the trunk will have a minor 
influence on whole body measurements. These assumptions are quite likely 
violated in obesity and conditions associated with fluid overload (e.g. heart or 
liver failure).55 Thus, segmental measurements have been purported to provide 
more accurate whole body estimates. However, in order to get to whole body 
estimates from segmental measurements, the bioimpedance data obtained from 
limb and trunk measurements must still be applied to regression-derived 
prediction equations developed from reference data, and have been shown to be 
erroneous in individuals with obesity and, as has been observed with all other 
bioimpedance approaches, the errors tend to increase with increasing 
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adiposity.96 The true potential advantage of segmental measurements is most 
likely to be evidenced in determining fluid shifts and distribution in individuals with 
fluid overload and those on dialysis.94 These applications will be discussed later 
on. 
Similar to the discussion regarding the use of SF-BIA devices to generate 
50 kHz PA and FFMI as potential parameters of nutritional status and/or clinical 
outcomes, there is growing interest in the application of an MF-BIA generated 
parameter, namely the ratio of impedance at 200 kHz to impedance at 5 kHz as a 
potential indicator of nutritional status97,98 and fluid overload.99–101 The advantage 
of an MF-BIA device over a SF-BIA device is that it can be used to generate all of 
these aforementioned parameters; these will be further discussed in subsequent 
sections.  
Bioimpedance Spectroscopy (BIS) 
The BIS approach for whole body measurements differs fundamentally 
from SF-BIA and MF-BIA. BIS devices have been commercially available since 
1990 when Xitron Technologies (San Diego, CA) introduced the first one onto the 
market (4000B). Although Xitron is no longer manufacturing BIS devices, they 
were pioneering in this field and now there are several companies producing 
them worldwide. These devices typically measure impedance at a minimum of 50 
frequencies over a spectrum of frequencies from very low to ~1000 kHz (see 
Table 1). Most commercially available BIS devices are programmed with 
modeling software that generates volumes through Cole modeling and 
subsequently applies the generated terms to modified versions of mixture 
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equations first developed by Xitron. Generally speaking, the software fits the 
impedance data (i.e. resistance and reactance) to the Cole model,102 a 
mathematical model shown to best describe this kind of physiologic data. With 
this procedure, non-linear least-squares curve fitting yields an interrupted 
semicircle (or impedance locus) that generates Cole model variables which can 
then be applied to equations to generate fluid volumes.72 Cole model terms 
include R0 (or Re, resistance associated with ECW), R∞ (sum of ECW and ICW 
resistances), Cm (cell membrane capacitance), and exponent α (accounts for 
distribution affects such as cell size and shape).72 Cole model term Ri (resistance 
associated with ICW) can further be computed with R∞ and Re or R0 variables 
using the following equation: 1/ Ri = 1/ R∞ - 1/ Re. 64,72 Characteristic frequency 
(fc), which is the frequency at which the effects of cell membrane capacitance 
are maximum is also calculated with the Cm, Re, and Ri terms as follows: 1/(2πCm 
[Re + Ri]),72 and is represented graphically as the point of maximal reactance in 
the Cole plot (i.e. the top middle point of the semicircle). Ideally, the data around 
fc are weighted to provide the best overall fit for the model.72 With this approach, 
ECW and ICW volumes are generated by applying Cole model terms to 
equations developed based on Hanai mixture theory which describes how 
electrical properties of tissues are modified by mixture effects of conducting 
(water, electrolytes, lean tissue) and non-conducting (bone, fat) components of 
the body.72,103 Theoretically, at zero frequency (with resistance R0), no 
conduction occurs and impedance (Z) is a function of ECW, i.e., Z = R0 = Re.72 At 
infinite frequency (with resistance R∞), pure conduction occurs and impedance is 
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a function of TBW, i.e., Z = R∞.72 These concepts have been thoroughly reviewed 
elsewhere80,104 and the Xitron mixture theory based BIS equations have been 
published previously.103,105 
In general, BIS has several theoretical advantages over SF-BIA and MF-
BIA in that it measures impedance over an entire range of frequencies, and does 
not depend upon population-specific prediction equations to generate whole body 
volumes and masses. The BIS approach is the only one that allows for the 
possibility of computing (through mathematical modeling) the characteristic 
frequency (fc), that changes with shifts in fluid compartments and cell 
membranes; and by measuring impedance up to very high frequencies, ensures 
that the characteristic frequency is reached, allowing for complete quantification 
of TBW. In addition, separate specific resistivity constants (derived from dilution 
references) for each of the fluid compartments (by gender) are applied to the 
volume  equations; thus, the BIS mixture equation approach does not assume 
that ECW and ICW are uniformly distributed.72 Therefore, this technique 
theoretically provides a more direct and individualized measure of ECW, ICW, 
and TBW compartments, compared to SF-BIA and MF-BIA approaches, which 
has potential advantages particularly in patient populations with altered fluid 
homeostasis.66,72 
However, there are several underlying assumptions to the original Xitron 
mixture equation approach that potentially introduce error to the volume 
estimates. There are several constants applied to the equations. Fixed (although 
separate) values for specific resistivity of the ECW and ICW compartments, and 
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constants for body density and shape are utilized in the equations. It is assumed 
that these constants are appropriate across the range of body composition; this 
is unlikely to hold true, particularly in individuals with excessive adiposity, and 
those with fluid imbalance associated with injury and disease. Indeed it has been 
well-documented that overestimation errors in TBW and FFM produced by the 
Xitron BIS equations increase with increasing adiposity67,69,70 and much of this 
error is attributed to the impact that adipose tissue can have on the specific 
resistivity of ICW.72,103 This limitation has been partially addressed by modifying 
the Xitron mixture equations with an adjustment for body mass index (BMI, 
kg/m2).103 
Moissl et al103 introduced a BIS approach termed as body composition 
spectroscopy (BCS), that involves the correction of the Xitron mixture equations 
for BMI, a surrogate for adiposity. The BCS approach was shown to improve 
volume estimates in individuals at the extremes of BMI. The BMI correction 
improved the standard error of the estimate for ICW by 24% for all subjects and 
by as much as 48% for the 24 subjects at BMIs < 20 and > 30.103 That said, the 
BCS approach is still associated with significant error in whole body estimates, 
particularly at the individual level. In the Moissl study, wide limits of agreement 
were observed in all fluid compartment estimates. Interestingly, in malnourished 
individuals with advanced cancer, the BCS approach was shown to reduce the 
underestimation of errors in FFM generated using BIS by 35% (Hydra 4200, 
Xitron Technologies) compared to DXA (Lunar DPX-L and Lunar Prodigy, GE 
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Healthcare); however, again substantial variability at the individual level was 
observed.106 
As stated previously for SF-BIA and MF-BIA, numerous validation studies 
in various healthy and clinical populations have been published on BIS 
(predominantly the original Xitron mixture equation approach), with similar 
findings of good mean level but poor individual level agreement between 
reference methods and BIS; much of the literature has been reviewed 
previously.56,66 Thus, although adjustment for BMI is an important advance for 
BIS, particularly in settings with extreme BMIs, further refinements are needed 
before it can be relied upon to accurately assess whole body masses and fluid 
volumes in the clinical setting. Nevertheless, the application of BIS (and MF-BIA) 
approaches for the monitoring of fluid status in individuals on dialysis is an active 
and growing area. Developments in the BIS technology for managing fluid 
balance are particularly promising, and will be discussed later. In addition, 
because BIS devices measure impedance data over the range of frequencies, 
they can easily be used to generate bioimpedance variables of interest including 
the 50 kHz PA and FFMI and the impedance ratio at 200/5 kHz (and potentially 
derivations unique to BIS, e.g. ratio of impedance at infinity/zero). These novel 
applications will be discussed next.
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Table 2-1: Selected Commercially Available Bioimpedance Devices (listed alphabetically by the device 
manufacturer)a. 
Manufacturer Device Method Price Rangeb Frequencies Measured 
BIOSPACE, Inc. 
Cerritos, California, USA 
InBody770 S-MF-BIA $15,000 - $ 20,000 1, 5, 50, 250, 500, and 1000 kHz 
InBody720 S-MF-BIA $15,000 - $ 20,000 1, 5, 50, 250, 500, and 1000 kHz 
InBody570 S-MF-BIA $5,000 - $10,000 5, 50, and 500 kHz 
InBody370 S-MF-BIA $5,000 - $10,000 5, 50, and 250 kHz 
InBody230 S-MF-BIA $5,000 - $10,000 20 and 100 kHz 
Bodystat Ltd 
Douglas, UK 
Bodystat 1500 SF-BIA $500 - $1,500 50 kHz 
Bodystat 1500 MDD MF-BIA $1,500 - $5,000 5 and 50 kHz 
QuadScan 4000 MF-BIA $5,000 - $10,000 5, 50, 100, and 200 kHz 
BBis~MultiScan 5000 BIS $10,000 - $15,000 50 frequencies from 5 to 1000 kHz 
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Manufacturer Device Method Price Rangeb Frequencies Measured 
Data Input 
Pöcking, Germany 
Nutribox SF-BIA $1,500 - $5,000 50 kHz 
Nutriguard-MS MF-BIA $1,500 - $5,000 5, 50, and 100 kHz 
Fresenius Kabi AG 
Bad Homburg, Germany 
BodyScoutc BIS NA 50 frequencies from 5 to 1000 kHz 
Fresenius Medical Care 
Bad Homburg, Germany 
Body Composition 
Monitorc 
BIS NA 50 frequencies from 5 to 1000 kHz 
ImpediMed 
Carlsbad, California, USA 
DF50 SF-BIA $1,500 - $5,000 50 kHz 
SFB7 BIS $15,000 - $20,000 256 frequencies between 4 and 1000 kHz 
Hydra 4200 (Xitron 
Technologies)d 
BIS NA 50 frequencies from 5 to 1000 kHz 
 34 
 
Manufacturer Device Method Price Rangeb Frequencies Measured 
Xitron 4000B (Xitron 
Technologies)d 
BIS NA 50 frequencies from 5 to 1000 kHz 
Maltron International Ltd 
Essex, UK 
BF-900 SF-BIA <$500 50 kHz 
BIOSCAN 920-II MF-BIA $10,000 - $15,000 5, 50, 100, and 200 kHz 
RJL Systems, Inc. 
Clinton Township, 
Michigan, USA 
Quantum II SF-BIA $1,500 - $5,000 50 kHz 
Quantum III SF-BIA $1,500 - $5,000 50 kHz 
Quantum IV SF-BIA $1,500 - $5,000 50 kHz 
Quantum X SF-BIA $1,500 - $5,000 50 kHz 
Quantum Desktop SF-BIA $5,000 - $10,000 50 kHz 
MC-780U MF-BIA $5,000 - $10,000 5, 50, and 250 kHz 
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Manufacturer Device Method Price Rangeb Frequencies Measured 
Tanita Corporation of 
America, Inc. 
Arlington Heights, Illinois, 
USA 
SC-331S SF-BIA $1,500 - $5,000 50 kHz 
BC-418 S-SF-BIA $5,000 - $10,000 50 kHz 
SC-240 SF-BIA $500 - $1,500 50 kHz 
SC-240IM SF-BIA $5,000 - $10,000 50 kHz 
TBF-410GS SF-BIA $1,500 - $5,000 50 kHz 
TBF-310GS SF-BIA $1,500 - $5,000 50 kHz 
TBF-300A SF-BIA $1,500 - $5,000 50 kHz 
TBF-300WA SF-BIA $1,500 - $5,000 50 kHz 
BF-350 SF-BIA $500 - $1,500 50 kHz 
Valhalla Scientific, Inc. G61-S SF-BIA $1,500 - $5,000 50 kHz 
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Manufacturer Device Method Price Rangeb Frequencies Measured 
Poway, California, USA G62-S SF-BIA $1,500 - $5,000 50 kHz 
G63-S SF-BIA $1,500 - $5,000 50 kHz 
G6 Duo SF-BIA $1,500 - $5,000 50 kHz 
BCS-1 SF-BIA $1,500 - $5,000 50 kHz 
BCS-2 SF-BIA $1,500 - $5,000 50 kHz 
BCS-3 SF-BIA $1,500 - $5,000 50 kHz 
Abbreviations: S-MF-BIA, Segmental Multiple-Frequency Bioelectrical Impedance Analysis; kHz, kilohertz; SF-BIA, Single-Frequency Bioelectrical 
Impedance Analysis; MF-BIA, Multiple-Frequency Bioelectrical Impedance Analysis; BIS, Bioimpedance Spectroscopy; S-SF-BIA, Segmental 
Single-Frequency Bioelectrical Impedance Analysis; NA, Not Applicable. 
aThis is not a complete list, and represents devices for which the pricing and other information was most readily available. Due to space 
constraints, we have not attempted to identify which devices provide raw data and/or the prediction equations used in their devices. Clinicians are 
advised to take these issues into consideration and obtain up to date information on the technical capacities before purchasing any bioimpedance 
device. 
b Approximations based on the current retail price of the devices as of October 2014. 
c Device not currently commercially available in the US as of October 2014. 
dDevice no longer commercially available in the US as of October 2014. 
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Novel Applications: Use of Bioimpedance Data for Clinical Assessment 
Due to the questionable validity of bioimpedance approaches for the 
assessment of whole body composition estimates in clinical populations, there is 
growing interest in the utility of the raw bioimpedance data for its potential to 
contribute to bed-side assessment of nutritional status and/or clinical outcomes. 
Bioimpedance-derived parameters (including 50 kHz measured PA, 50 kHz 
FFMI, and 200/5 kHz impedance ratio) have been investigated as potential 
prognostic indicators of mortality, disease severity, morbidity, hydration status, 
and malnutrition.46,85 The use of such data is mostly independent of regression 
equations (except for FFMI) and may be potentially useful in situations where 
assumptions for whole body composition estimates are likely to be violated.  
Phase Angle (PA) 
Phase angle (PA) is the ratio of the arc tangent of reactance to resistance, 
and is purported to relate to important cellular characteristics, including 
membrane capacitance, integrity, and permeability, as well as overall size and 
hydration.107,108 Although PA can be calculated at any frequency, the PA 
measured at 50 kHz has been the primary clinical parameter of interest due to 
the wide availability and predominance of SF-BIA devices. Moving forward, we 
will use “PA” to indicate PA measured at 50 kHz. A higher PA indicates a 
proportionally greater reactance for a given resistance, which has been 
interpreted to suggest more intact cell membranes and higher BCM.85,109 On the 
other hand, a lower PA has been interpreted to indicate cell loss and decreased 
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cell integrity and BCM.109 Clinically, a low PA has been studied as a prognostic 
indicator of disease and/or nutritional risk in HIV infection,110,111 cirrhosis,112 
hemodialysis,113 cancer,107,114–116 chronic heart failure117 and geriatric settings,118 
where cell membrane integrity is likely to be compromised and fluid-based 
alterations are common.85,108,116 Additionally, a low pre-operative PA has been 
shown to be associated with poor nutritional and clinical outcomes among 
individuals undergoing cardiac119 and gastrointestinal120–122 surgeries. In one of 
the more recent reports, Kyle et al108 observed that when compared with healthy 
controls, hospitalized patients had a lower PA (<5.0° in men, <4.6° in women, 
using a SF-BIA device [RJL-101, RJL Systems; no longer commercially 
available]) that was significantly associated with lower FFM and a higher 
percentage of body fat. Additionally, patients at moderate and severe nutritional 
risk (identified by Nutritional Risk Screening [NRS-2002] and Subjective Global 
Assessment [SGA]) were more likely to have low PA than healthy controls.108 In 
this study, hospital length of stay (LOS) and non-survival were also associated 
with a lower PA.108 
In a series of other investigations, Gupta and colleagues107,114–116 reported 
that PA measured by a SF-BIA device (BIA-101Q, RJL Systems; no longer 
commercially available) was an independent prognostic indicator in individuals 
with advanced pancreatic (stage IV), advanced lung (stages IIIb and IV), 
advanced colorectal (stages II and IV), and breast cancer (stages I – IV). For 
example, using the nutrition assessment tool SGA, this research team identified 
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various PA cut-points to identify well-nourished or malnourished individuals with 
advanced colorectal cancer.115 Individuals classified as malnourished by the SGA 
had a significantly lower median PA score than well-nourished individuals (5.18° 
vs. 6.12°, p=0.005), and a modest but significant correlation was found between 
the SGA and PA scores (r=0.33, p=0.004).115  
The primary challenge of using PA for clinical assessment is the lack of 
consensus on cut-points to be used to identify malnutrition (or poor clinical 
outcomes). Although several investigators around the globe have generated 
reference values for PA based on large population samples including healthy 
Swiss,123 German,87,88 and American86 adults, notable differences have been 
observed. It is not entirely clear whether these differences are solely population 
dependent or if differences among devices used are contributory. It has been 
observed86 that PA reference values generated by the RJL-101 device from 
healthy US adults were higher than those generated for healthy Swiss adults 
using various devices including the RJL-101 and 109 (SF-BIA devices no longer 
commercially available) and the Xitron Technologies 4000B (a BIS device no 
longer commercially available),123 even after adjusting for BMI and percent fat 
mass. Although the use of different devices could have introduced some variation 
in these results, a more likely explanation is the ethnicity-specific differences in 
relative leg length, frame size, and body build.55 Therefore, standardized 
population-specific reference data are likely to be necessary for optimal 
interpretation and application. For example, among individuals with cancer 
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(mostly with gastrointestinal tumors), Norman et al89 evaluated PA measured by 
a MF-BIA device (Nutriguard M, Data Input; no longer  commercially available) 
using the age-, sex-, and BMI-stratified data that was previously generated for 
the healthy German population.87 In this way, a standardized PA value was 
generated for each patient. Individuals with a standardized PA value below the 
5th percentile exhibited impaired nutritional and functional status, diminished 
quality-of-life, higher LOS, and a significantly higher 6-month mortality risk when 
compared to individuals with PA values above the 5th percentile.89 
Additional research on the applications of standardized PA data for clinical 
assessment is vitally needed. It is unclear whether adjustments can be made to 
align reference data generated from different populations using different devices. 
Furthermore, additional research is needed to see if standardized PA can be 
used to identify muscle loss as one of the diagnostic markers of malnutrition.3 
With additional research in this area, it is certainly possible that standardized PA 
might prove to be a useful index of nutritional status in the clinical setting; 
however, its use as an assessment tool is limited by the lack of clear and 
consistent reference cut-points. 
Impedance Ratio (IR) 
Another bioimpedance parameter that has been proposed as a potential 
indicator of nutritional status and/or clinical outcomes is the ratio of impedance 
measured at 200 kHz to impedance measured at 5 kHz. This has been termed 
“impedance ratio” (IR) or “prediction marker” (introduced as such by Bodystat®) 
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and will be designated in this discussion as IR. With impedance measurements 
at high (200 kHz) and low (5 kHz) frequencies, the IR parameter has been 
suggested to reflect the ratio of ECW/TBW fluid distribution. There are a limited 
number of published studies that have investigated the clinical utility of IR. 
Although normal reference cut-points have not yet been established as they have 
for PA, IR values ≤ 0.78 in males and  ≤ 0.82 in females have been observed in 
healthy individuals.98 IR values approaching 1.0 suggest that the two measured 
impedances are approaching each other in value; higher IR values have been 
associated with post-operative edema,99 worsening renal100 and cardiac101 
function, and poor nutritional status.97,98 
Several studies have evaluated IR as a surrogate marker for clinical 
outcomes associated with fluid overload. Among 38 individuals undergoing major 
abdominal surgery, pre-operative IR measured by a MF-BIA device (QuadScan 
4000, Bodystat) was significantly higher in the 20 participants who developed 
post-operative edema compared to individuals who did not develop edema later 
on (0.81±0.03 versus 0.78±0.02; p=0.015).99 In another observation, an IR value 
of >0.85 (QuadScan 4000) was found to be an independent predictor of 
worsening renal function among 80 patients hospitalized with decompensated 
heart failure.100 Similarly, among 243 individuals with chronic heart failure, 
gender-adjusted IR values (QuadScan 4000) were significantly higher (e.g. 0.85 
vs 0.82 for females; 0.83 vs 0.80 for males) and gender-adjusted PA values were 
significantly lower (e.g. 4.2 vs 5.1 for females; 4.9 vs 5.7 for males) in the Class 
 42 
 
III-IV New York Heart Association (NYHA) functional classification group 
(indicative of more severe cardiac symptoms) compared to Class I-II NYHA 
group (less severe cardiac symptoms).101 These findings suggest that whole 
body MF-BIA derived IR may be useful in identifying individuals who already 
have or are at risk for developing fluid overload, which carries risk for poor 
clinical outcomes. 
Other lines of investigation have evaluated IR as a potential marker for 
malnutrition. In one limited analysis of 316 hospitalized patients with IR values 
between 0.75 – 1.0 on admission measured using a BIS device (Hydra 4200S, 
Xitron Technologies; no longer commercially available), 27% of whom were 
malnourished, a higher IR was associated with greater risk for malnutrition 
(defined as weight loss > 5% in 1 month or >10% in 6 months and/or BMI <18.5) 
and longer length of stay in the hospital.97 Specifically, for each 0.10 increase in 
IR above 0.75 at admission, the odds ratio of severe malnutrition was 5.8 (95% 
Confidence Interval [CI], 2.7 – 12.5; p<0.001) and LOS increased by 4.2±1.7 
days (p=0.013). Similar but less robust findings were observed for PA; for each 
1.0 unit decrease in PA at admission, the odds ratio of severe malnutrition was 
2.0 (95% CI, 1.2 – 3.6; p=0.011) and LOS increased by 2.3±1.2 days 
(p=0.056).97 In a similar observation among 109 individuals with gastrointestinal 
disorders, IR and PA (Xitron 4000B BIS device for IR, RJL BIA 101 SF-BIA 
device for PA) were evaluated for their ability to identify individuals with 
malnutrition assessed by neutron activation analysis derived total body protein 
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measurements.98 In this report, a higher IR (high IR defined as values >0.82 for 
females, and >0.78 for males, from 151 healthy volunteers) was associated with 
a 4.15-fold higher odds of being malnourished, whereas the odds ratio for a lower 
PA was 1.55.98 Additionally, from a total of 71 identified malnourished individuals, 
56 were detected by IR, compared to 16 individuals identified by PA; each 0.10 
increase in IR and each unit decrease in PA was associated with a 4.64-fold and 
a 1.55 fold increased odds of malnutrition, respectively.98  
The limited research conducted to date seems to suggest that IR and PA 
may have clinical utility for identifying malnutrition at the bed-side; however, 
additional research is needed to better identify standardized cut-points and to 
validate those cut-points in terms of current malnutrition criteria3 and ideally, 
against reference methods for lean tissue (i.e. to establish if clinicians can use 
PA and/or IR to identify individuals with muscle loss in addition to identifying 
individuals with overall malnutrition). 
Fat-Free Mass Index (FFMI) 
Kyle et al90,124 have proposed the use of FFMI, calculated as the ratio 
between FFM calculated from their published 50 kHz bioimpedance equation123 
and height (kg/m2), as a standardized, height-independent nutrition assessment 
method.  Although FFMI is not in the same category as PA and impedance ratio 
(because it requires the use of a prediction equation for FFM), it has similarly 
been studied for its potential to predict nutritional status and/or clinical outcomes. 
The interest in FFMI has arisen in part due to the challenges described earlier for 
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generating whole body FFM estimates by bioimpedance. Furthermore, from a 
theoretical perspective, it is challenging to interpret the absolute values of FFM in 
kilograms (kg) measured by any technique, as estimates increase with height 
and decrease with body weight, age, illness, and gender differences.90,123,124 This 
group has published normative data for FFMI developed from measurements in 
healthy Swiss adults90 and FFMI cutoff values for various BMI categories have 
also been reported in this population.124 
Several studies have investigated the clinical utility of FFMI. In a 
prospective observational study involving 325 cardiac surgery patients in the 
Netherlands, pre-operative FFMI calculated from the 50 kHz data generated by a 
BIS device (BodyScout, Fresenius Kabi; not currently commercially available in 
the US) was evaluated for various post-operative outcomes.125 A low FFMI value 
was set at ≤14.6 kg/m2 in women and ≤16.7 kg/m2 in men using previously 
published normative Swiss population data.124 It was reported that a low pre-
operative FFMI was independently associated with a higher occurrence of post-
operative infections and longer LOS in the intensive care unit.125 More recently, 
among 123 pre-operative abdominal surgery patients in the Netherlands, FFMI 
estimates generated by two different devices were compared (BF-906, Maltron 
International Ltd [a SF-BIA device] and BodyScout [a BIS device]).126 In this 
study, the BIS device identified a larger proportion of patients with lower FFMI 
(47%) compared to the SF-BIA device (16%) (p<0.001).126 Limits of agreement 
between the two devices indicated that the SF-BIA device overestimated the 
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values compared to the BIS device for both FFM (4.93±6.22 kg) and FFMI (1.66± 
2.25 kg/m2).126 These results point to the challenges inherent in applying FFMI as 
an indicator of nutritional status when potentially using a different device from 
that used to generate reference cut-points. As mentioned for PA and IR, 
additional research is needed to determine how FFMI might be utilized as a tool 
for nutritional assessment in the clinical setting. 
Use of Bioimpedance Techniques for Evaluation of Lymphedema and Fluid 
Management in Dialysis 
Beyond its potential role in nutrition assessment, there has been 
substantial interest from the medical community in the application of 
bioimpedance for the assessment of various aspects of clinical care including 
wound healing,127 neuromuscular disease progression,128,129 cardiac output 
monitoring,130–133 and conditions associated with expanded ECW.134–136 The 
reader is referred to the excellent review by Lukaski64 for a more complete 
description of these novel applications of bioimpedance. Here, we will discuss 
the two most prominent examples of the application of bioimpedance for 
assessment of conditions associated with expanded ECW: the evaluation of 
lymphedema and the management of fluid balance in individuals on dialysis. 
Evaluation of Lymphedema 
Lymphedema is the swelling that occurs when protein-rich lymph fluid 
accumulates in the interstitial space,137 resulting from damaged or blocked 
lymphatic vessels that inhibit the drainage of fluid from tissues. This 
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subcutaneous accumulation of lymph fluid is associated with the expansion of 
ECW.138 Secondary lymphedema of one or both arms or legs is a debilitating 
consequence of cancer or its treatment that is particularly prevalent among 
individuals with breast, uterine, ovarian, and prostate carcinomas, and 
lymphomas or melanomas.137 Although incurable, early detection through regular 
monitoring is one of the best ways to promptly manage lymphedema.137,138 
There has been significant interest in the application of segmental BIS to 
monitor and detect early stages of lymphedema particularly among individuals 
with breast cancer. Much of the early work in this area involved the application of 
a BIS device to generate an inter-limb ratio of resistance values for an affected 
limb compared to an unaffected limb.138–143 In brief, the BIS device is used to 
generate Cole model terms and the resistance at zero kHz (R0) for the unaffected 
limb is divided by the R0 for the affected limb. Among women diagnosed with 
unilateral arm lymphedema post breast-cancer treatment, Ward et al144 used the 
aforementioned ratio method to generate the ECW/ICW ratio and volume of the 
affected arm using a BIS device (SFB7, ImpediMed). The mean arm ECW/ICW 
ratio was 1.5:1 among those with lymphedema, compared to values between 
0.85:1 and 1:1 in the group without lymphedema.144 When compared with the 
reference method perometry (which provides more direct measures of limb 
volume), BIS showed proportional increases in arm size and strong correlations 
were noted between the two measures for ECW, ICW, and TBW compartments 
(r=0.80–0.90).144 In a further evaluation of this technique among women with 
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lymphedema and those with no history of lymphedema, Czerniec et al139 reported 
that when compared with perometry-derived volume data, segmental BIS using 
the SFB7 device detected mild localized lymphedema; however, it should be 
noted that the limits of agreement between the two methods varied from 8.5% for 
the upper arm segment to16.6% for the forearm segment, with increases in bias 
with the severity of lymphedema.139 The authors have asserted that because BIS 
is sensitive to changes in the ECW volume, the method is able to detect mild 
localized lymphedema better than perometry. However, evaluation of the 
absolute accuracy of BIS-guided limb volume estimations is difficult to achieve 
due to limitations inherent to perometry and other reference methods and the 
lack of segment-specific normative data for limbs. Regardless, this segmental 
BIS approach appears to hold promise for the early detection of lymphedema in 
its latent stages and therefore merits additional research. 
Fluid Management in Dialysis 
Overhydration characterized by expansion of the ECW is common among 
individuals on dialysis,72 and bioimpedance techniques have been investigated 
for monitoring hydration status and adjusting dialysis treatment goals. The 
primary target of interest is the estimation of ‘dry weight’, which has been defined 
as the lowest tolerable post-dialysis weight at which the patient is as close as 
possible to a normal hydration state without experiencing symptoms associated 
with either overhydration or underhydration.145,146 Dry weight is technically 
achieved through the removal of excess water during dialysis.146 Estimates of dry 
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weight are further used to calculate the ultrafiltration rate, or the rate at which the 
fluid is removed during the course of dialysis. Clinical assessment of dry weight 
is critical because an overestimation of dry weight could result in inadequate 
ultrafiltration and hypervolemia and its associated symptoms including arterial 
hypertension, left ventricular dilatation, and left ventricular hypertrophy.145,146 An 
underestimation of dry weight, on the other hand, could result in excessive 
ultrafiltration and hypovolemia, which could lead to hypotension, arrhythmias, 
reduced compliance to treatment, and an increased risk of vascular 
thrombosis.146,147 The clinical estimation of dry weight has been mostly through 
trial and error methods that involve parameters such as physical examination, 
changes in blood pressure or respiration rate, or presence of edema, without 
actually quantifying changes in fluid volume.146,147 Thus bioimpedance 
techniques have been explored for their ability to estimate dry weight in 
individuals on dialysis. 
Segmental Measurements 
One approach that has been studied is the use of continuous segmental 
BIS measurements of the calf during hemodialysis. The assumption underlying 
this approach is that due to gravity effects, the calf would be the last section of 
the body from which excess ECW is likely to be removed and thus it has been 
identified as an ideal region to target for measurement given that the relative fluid 
volume of excess ECW would be expected to be higher in the calf region 
compared with the arms or trunk.145,148 By this approach, the dry weight is 
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identified when the ECW volume in the calf does not decrease further, despite 
ongoing ultrafiltration. Hence this method identifies the time-point during dialysis 
at which an individual is assumed to be at his/her dry weight, and thus 
ultrafiltration should be stopped.145,148 One of the limitations of this method is that 
it does not provide a whole body target volume to be removed at the initiation of 
dialysis, because the dry weight is identified during ongoing dialysis and the 
excess fluid removed at the whole body level is not quantified.149 
In a derivation of this approach, Zhou and colleagues147 used a MF-BIA 
device (QuadScan, Bodystat) to generate the IR from a segmental measurement 
of the calf to estimate dry weight in individuals on hemodialysis. Age-stratified 
calf impedance ratio values were obtained from healthy controls and set as target 
impedance ratios. In this study, calf IR was measured 30 minutes after the 
completion of a mid-week dialysis session, and dry weight was incrementally 
decreased at each subsequent dialysis session (or on a weekly basis) until the 
target calf IR was reached or symptoms of hypovolemia occurred. Achievement 
of target calf IR values in this study was associated with a significant reduction of 
blood pressure and use of antihypertensive medications.147  
Wrist-Ankle Measurements 
Significant recent advancements in the BIS technology provide a novel 
and promising approach to the fluid management of individuals on dialysis with 
potential ramifications for other clinical populations. These developments involve 
the refinement of the whole body wrist-ankle BIS approach to incorporate a new 
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model of body composition.83 Essentially, the BMI-corrected mixture equations 
described earlier as the BCS approach103 are used to generate ECW and ICW 
volumes that are then applied to model equations proposed by Chamney et al83 
that attempt to differentiate excess fluid from normally hydrated tissue. In this 3-
compartmental model of body composition, the body is delineated into normally 
hydrated adipose tissue mass (NH_AT), normally hydrated lean tissue mass 
(NH_LT), and excess fluid mass (ExF).83  
This new approach has been evaluated in several studies. Wizemann et 
al150 used the Body Composition Monitor BIS device (Fresenius Medical Care; 
not currently commercially available in the US), which incorporates the 
aforementioned approach into its software based on previous work,83,151 to 
estimate overhydration and predict mortality among 269 chronic HD patients 
during a follow-up period of 3.5 years. The device software is programmed with 
expected normal values for ECW for a given body weight and composition based 
on healthy population data; absolute fluid overload is determined by the 
difference between the normal expected ECW and the actual measured ECW. 
The relative fluid overload is expressed as the ratio between the absolute fluid 
overload and the ECW. Wizemann et al150 reported that the pre-dialysis relative 
fluid overload was an independent predictor of mortality, with a hazard ratio (HR) 
of 2.1 (95% CI, 1.39 - 3.18; p=0.003). In a similar study among 529 individuals on 
peritoneal dialysis, the Body Composition Monitor-derived relative fluid overload 
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was also found to be an independent predictor of mortality (HR=2.09, 95% 
CI,1.19 - 2.82; p<0.001).152 
Recently in a prospective randomized trial, Body Composition Monitor-
derived ECW, ICW, and TBW volumes were used to adjust dry weight and 
prescribe ultrafiltration goals for HD patients over a period of 2.5 years.153 A total 
of 131 patients were randomized into the ‘bioimpedance group’ (n=62), where 
target dry weight was prescribed based on the read-outs from the BIS device, 
and the ‘control group’ (n=69), where dry weight was determined based on the 
blood pressure value, presence of edema, and other physical parameters.153 
Compared to the control group, all-cause mortality, arterial stiffness, blood 
pressure, and relative fluid overload were significantly lower in patients who 
received the BIS-guided dry weight adjustment.153  
Taken together, these study results are strongly supportive of the 
application of BIS, in particular the approach incorporated into the Body 
Composition Monitor software, for the clinical assessment of dry weight in 
individuals undergoing dialysis. Additional research investigating outcomes 
including morbidity and mortality in individuals with dialysis being managed with 
this approach is certainly warranted. Furthermore, the apparent effectiveness of 
this new 3 compartment model BIS approach in the fluid management of 
individuals on dialysis carries great potential for application to other clinical 
conditions associated with fluid overload including heart and other organ failure, 
sepsis, trauma, and other critical illness. Moreover, the ability to differentiate 
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between excess fluid and this model’s concept of normally hydrated lean tissue 
holds promise, particularly if it can be refined to provide meaningful estimates of 
lean tissue for nutritional assessment purposes. Additional research is definitely 
warranted.   
Summary and Conclusions 
In this update, we have reviewed the three primary categories of 
bioimpedance techniques in terms of underlying assumptions, strengths, and 
limitations in order to orient clinicians to the differences between approaches, 
and the potential opportunities for their application in the clinical setting. The 
global interest in these techniques to provide whole body estimates of lean tissue 
for bed-side nutritional assessment has led to substantial validation research 
efforts to provide proof of their accuracy and reliability, with mixed results. 
Predominant reports of large variability in individual estimates by bioimpedance 
and reference techniques have led to a general mistrust of bioimpedance 
methods to quantify whole body composition in clinical populations, particularly 
those with abnormal body geometry and fluid balance. Reliance on statistical 
methods that may not adequately account for errors in reference techniques and 
cross-validation of SF-BIA and MF-BIA equations originally developed from one 
reference method by comparison to a different reference method are just two of 
the limitations in the validation literature that may contribute to the 
inconsistencies regarding validity across studies. Thus, it remains somewhat 
unclear if any bioimpedance technique can be proven to provide sufficiently 
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meaningful whole body lean tissue estimates at the individual bed-side to 
appropriately identify individuals with malnutrition and/or to effectively monitor 
lean tissue changes in response to nutritional interventions. The new 
developments in BIS technology that are being applied in individuals on dialysis 
hold promise; the improvements in the ability of BIS devices to quantify excess 
fluid in these patients using new models of body composition could lead to further 
refinements for the assessment of lean tissue in other clinical populations.  
The SF-BIA and MF-BIA approaches for whole body lean tissue 
assessment are likely to remain somewhat limited for use in the clinical setting. 
Although clinicians might optimize accuracy in whole body estimates generated 
by a particular SF-BIA or MF-BIA device by choosing an appropriate equation 
from the literature that matches the characteristics of their particular patient, it is 
not very practical to expect this to happen in the clinical setting. Many 
bioimpedance devices have a “black box” approach where programmed 
equations are kept as proprietary information so clinicians have no idea of what 
equation is being used. Furthermore, some devices do not provide the raw 
bioimpedance data, and thus clinicians have no way to recalculate their own 
estimates of body composition, even if they are able to find the time to identify an 
appropriate prediction equation. Taken together, these concerns have led to the 
pursuit of using raw bioimpedance data for the evaluation of nutritional status 
and/or clinical outcomes independent of whole body composition estimates. 
Although these applications appear promising, they are limited by the lack of 
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consensus on reference cut-points. From the literature on PA and FFMI, it 
appears that there may be potentially important population- and device-specific 
differences in reference values; the ongoing turnover of devices in the market 
place is a significant consideration. Moreover, these applications require further 
study to determine if they can be used to accurately identify individuals with 
malnutrition and/or monitor response to nutritional interventions. There is clearly 
a need for additional research investigating the applications of bioimpedance for 
clinical assessment of malnutrition and response to nutritional interventions. Two 
specific questions that merit further investigation are: 
 Can the application of PA and/or IR be sufficiently refined (i.e. with clear 
cut-points) to be useful for the diagnosis of sarcopenia (with and without 
the presence of obesity) and malnutrition in clinical settings?  
 Can BIS derived “normally hydrated lean tissue mass” as generated from 
the new BIS models being applied in dialysis be used to effectively identify 
malnutrition and evaluate responses to nutritional interventions at the bed-
side? 
Obtaining answers to these questions will likely require the design of rigorous 
clinical trials that incorporate appropriate reference techniques and solid 
statistical design, and the cooperation of the bioimpedance manufacturing 
industry. 
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Overall Summary and Current Study 
In summary, although malnutrition has been recognized as a significant 
clinical problem among individuals with HNC, its prevalence has not been well-
documented due to a lack of consensus on definition and diagnosis. Malnutrition 
and a delay in the administration of nutritional intervention are associated with 
negative clinical outcomes including poor QoL and functional status, hospital 
readmissions, and increased infectious complications. This is particularly relevant 
among individuals with HNC, who, if not already malnourished at the time of 
diagnosis, frequently become malnourished as a result of treatment-induced 
weight loss, loss of appetite, taste changes, and reduced oral intake. Studies 
investigating the applications of bioimpedance for the clinical assessment of 
malnutrition are limited among individuals with HNC. Further, the relationship 
between psychosocial measures such as the QoL and self-efficacy and 
nutritional outcomes also warrants additional research in this patient population. 
The following chapters will address these notable gaps in HNC related 
research. Chapter 3 estimates the prevalence of malnutrition among individuals 
with HNC during and up to 3 months after treatment, testing the hypothesis that 
the prevalence of malnutrition will be higher at the completion of treatment when 
compared to the start of treatment and the later post-treatment period. Chapter 3 
also investigates the utility of raw bioimpedance parameters such as the 50 kHz 
phase angle and 200 kHz/5kHz impedance ratio to identify individuals with 
malnutrition, testing the hypothesis that malnourished individuals will exhibit 
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lower phase angle and higher impedance ratio when compared to those who are 
well-nourished. Chapter 4 evaluates whether malnutrition relates to QoL and 
coping self-efficacy among individuals with HNC before and after treatment 
completion, testing the hypothesis that malnourished individuals will report 
having a lower QoL and self-efficacy scores when compared to those who are 
well-malnourished. Finally, Chapter 5 provides an overall conclusion and 
suggestions for future directions. 
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CHAPTER 3: NUTRITIONAL STATUS AND BODY COMPOSITION AMONG 
INDIVIDUALS WITH ADVANCED HEAD AND NECK CANCER: A 
PROSPECTIVE INVESTIGATION IN AN OUTPATIENT SETTING. 
 58 
 
Introduction 
Malnutrition, generally defined as a decline in lean body mass with 
functional impairment at the molecular, physiologic, and/or motor levels,3 is highly 
prevalent among individuals with head and neck cancer (HNC), with up to 40% –
57% with a compromised nutritional status even before beginning their 
treatment.1,11 Malnutrition has been associated with poor survival outcomes, 
post-surgical complications, risk of infections, impaired wound healing and 
recovery, declining quality of life and functional status, and poor disease 
prognosis.1,8,11–15 From the health care perspective, malnutrition is associated 
with frequent treatment interruptions and increased hospital readmissions and 
length of stay, further adding to patient and hospital care related costs.2,3 
Although malnutrition has been recognized as a significant clinical 
problem in the HNC population, its prevalence has not been well-documented in 
the US due to a lack of consensus on malnutrition diagnosis and definition.  
Standardized protocols for screening, assessment, and intervention for 
malnutrition in this population are lacking, due in large part to a paucity of data.  
The 2012 Academy of Nutrition and Dietetics (the Academy) and American 
Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Consensus Statement 
on adult malnutrition has suggested the use of two or more of the following six 
markers for diagnosis: insufficient energy intake, unintended weight loss, loss of 
muscle mass, loss of subcutaneous fat, localized or general fluid accumulation, 
and diminished functional status as measured by hand grip strength.3 The 
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efficacy of the new Consensus framework in identifying those at risk for 
malnutrition has not been examined among individuals with HNC in an outpatient 
setting. Therefore using the new malnutrition diagnosis, the purpose of this 
prospective, natural history pilot study is to identify the prevalence of malnutrition 
among individuals with HNC at one outpatient clinic during and up to 3 months 
after treatment completion. We used the scored Patient-Generated Subjective 
Global Assessment (PG-SGA) as the reference standard to evaluate the 
sensitivity and specificity of the Consensus framework in defining malnutrition. 
Knowing that the loss of muscle mass is one of the defining characteristics 
of the new malnutrition framework, there has been a growing interest in the use 
of body composition techniques to assess lean tissue at the bedside. For this 
purpose, bioimpedance techniques have been widely appreciated for their non-
invasiveness, safety, ease of use, and portability, and as lower cost alternatives 
for lean tissue assessment.154 Although the utility of raw bioimpedance data in 
the bedside assessment of nutrition status has been emerging in the research 
literature,55,154 these data have not been validated in terms of the recent 
malnutrition criteria. Therefore we also investigated whether clinicians can 
potentially use the bioimpedance parameters such as phase angle and 
impedance ratio to identify individuals with overall malnutrition, and how 
bioimpedance markers relate to functional status outcomes.  
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Methods 
Study Participants and Time-points 
This study included 19 individuals with head and neck cancer intending to 
undergo treatment with concurrent chemoradiotherapy (CRT) at the Masonic 
Cancer Clinic and Radiation Oncology Clinic at the University of Minnesota 
Medical Center, Fairview. All participants classified themselves as Caucasian. 
Specifically, individuals ≥ 18 years of age with pathologically confirmed 
squamous cell cancers of the oral cavity, oropharynx, hypopharynx, larynx and 
maxillary sinuses were included in the study. Individuals with pacemakers or 
other similar internally placed biomedical devices were excluded as it is not 
recommended that these individuals undergo testing by bioimpedance devices. 
Beginning December 2013 through March 2015, data were collected 
during routine care when individuals were attending the clinics for their CRT 
appointments and post-treatment follow-up visits. The five time-points of this 
study were as follows (see Figure 3-1): Time 1 (T1), within 7 days prior to 
starting the CRT; Time 2 (T2), 3.5 weeks (about midpoint) into treatment ± 1 
week; Time 3 (T3), during the last week of treatment; Time 4 (T4), follow-up, 1 
month after the completion of treatment ± 14 days; and Time 5 (T5), follow-up, 3 
months after the completion of treatment ± 1 month. The time-points for this 
study were established in order to evaluate and assess any changes in nutrition-
related parameters during and after treatment completion. Overall, 85 
independent study visits were completed and each visit lasted up to 1.5 hours in 
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duration. Five participants missed one study visit, one individual missed two 
visits, while another missed three visits. Reasons for absence were changes in 
the treatment plan for four individuals, death in two cases, and declining to 
participate in one case. The Institutional Review Board and the Cancer Protocol 
Review Committee (Masonic Cancer Center) at the University of Minnesota 
(UMN) approved this study. Study data were entered and managed using the 
REDCap electronic data capture tools hosted at the UMN.155 
Anthropometric Procedures 
Anthropometric data were collected by a researcher trained in recording 
height, weight, skinfolds and arm circumference measurements. Using standard 
protocols,156 height was recorded to the nearest 0.1 cm and body weight to the 
nearest 0.1 kg.  Body Mass Index (BMI) was calculated by dividing the 
participant’s weight in kilograms by the squared value of their height in meters: 
[weight (kg)/ (height (m))2]. BMI was categorized based on the National Heart, 
Lung, and Blood Institute’s classification (National Institutes of Health, 2015). 
Percent weight loss was calculated as [(Usual Body Weight – Actual Body 
Weight)/ Usual Body Weight] * 100. Using the cut-points identified in the 
Consensus criteria,3 unintended weight loss was used to assess the severity of 
malnutrition as follows: weight loss of > 5% in the past month or >10% in the past 
6 months was a marker for severe malnutrition; weight loss of 5% in the past 
month or 10% in the past 6 months was a marker for nonsevere (moderate) 
malnutrition. 
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Triceps skinfold thickness (TSF) was measured to the nearest 0.1 mm and 
mid-upper-arm circumference (MUAC) was measured to the nearest 0.1 cm.156 
Three sequential measurements were recorded for TSF and MUAC, and the 
average of the three values were used for analysis.  
Nutrition-focused Physical Exam 
Three out of the six Consensus markers were evaluated through the 
nutrition-focused physical exam. Using the physical assessment guidelines 
provided by Malone and Hamilton,157 a nutrition-focused physical exam was 
conducted by one researcher at each time point to assess the presence of 
muscle and/or subcutaneous fat loss and fluid accumulation. At one time 
towards the beginning and once towards the end of the study, another 
researcher independently conducted the physical exam, and inter-observer 
agreement was noted in the overall subjective ratings between the two 
researchers. 
Dietary Intake: 24-hour Dietary Recall and 3-day Food Records 
A researcher with experience in collecting dietary recalls conducted the 
24-hour recall at each of the five time points. A four stage, multiple-pass 
interviewing technique was used, that included 1) obtaining a complete list of 
foods and beverages consumed; 2) detailed description of each item including 
cooking methods and brand names; 3) collecting estimates of the amounts and 
portion sizes of the items consumed, and 4) reviewing the information to ensure 
that all items were entered correctly.158 
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Starting at Time 1, participants were given an orientation by the 
researcher on how to keep accurate dietary records, including reading nutrition 
labels, using measurement aids, estimating portion sizes, and reporting mixed 
dishes (Appendix B). Individuals were asked to bring the 3-day dietary records to 
their next clinic appointment beginning Time 2 through Time 5.  Diet records 
were reviewed with the participants during each follow-up visit. Dietary intake 
data were collected and analyzed using the Nutrition Data System for Research 
software (2014) developed by the Nutrition Coordinating Center, UMN, 
Minneapolis, MN. The 24-hour dietary recall and the 3-day food records were 
analyzed in order to estimate an average 3 - 4 day intake for calories and protein. 
Estimated energy requirements were calculated as 25 kcal/kg ideal body 
weight for obese individuals; 30 kcal/kg actual body weight for overweight, and 
35 kcal/kg actual body weight for normal weight individuals.159 Percent energy 
intake was calculated as follows: (Recent intake/Estimated intake)*100, and 
intake ≤ 75% of estimated energy requirement for ≥ 1 month was the marker for 
severe malnutrition and < 75% of estimated energy requirement for ≥ 1 month 
was considered as a marker for nonsevere (moderate) malnutrition.3  
Scored Patient-Generated Subjective Global Assessment (PG-SGA) 
Nutritional status was also assessed using the features of the PG-SGA, 
which included information on medical history that was completed by the 
participant; features include weight change, changes in dietary intake, nutritional 
and gastrointestinal symptoms, and functional capacity (Appendix C).160 The 
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study researcher completed the remainder of the form that included other 
disease-related information and its relation to the patient’s nutritional 
requirements and estimated level of metabolic stress. Additionally, a thorough 
nutrition-focused physical exam was conducted that subjectively evaluated 
changes in fat, muscle, and fluid status.160 
Based on the overall subjective ranking for nutritional and functional 
status, individuals were rated as being well nourished or anabolic (SGA-A); 
moderately malnourished or suspected of malnutrition (SGA-B); or severely 
malnourished (SGA-C). Additionally, a total numerical score was calculated from 
history, disease condition, metabolic demand, and physical examination 
components of the PG-SGA tool. Per this scoring process, a score ≥ 9 indicated 
a critical need for improved symptom management and nutrient intervention.161  
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Figure 3-1: An outline depicting various study time points and measures. 
                        
 
 
Time 1 
(Within 7 
days prior 
to starting 
CRT) 
Time 2 
(3.5 weeks 
into treatment  
± 1 week) 
Time 3 
(During the 
last week of 
treatment) 
 
Time 4 
(Follow-up, 1 
month post 
treatment  
± 14 days) 
 
Time 5 
(Follow-up, 3 
months post 
treatment 
± 1 month) 
MEASURES  
Anthropometrics          
Height X     
Weight X X X X X 
Triceps skinfold X X X X X 
Mid-upper-arm circumference  X X X X X 
Body composition      
   Bioimpedance X X X X X 
Scored Patient-Generated Subjective Global 
Assessment (PG-SGA) 
X X X X X 
Dietary intake data      
   24-hr dietary recall X X X X X 
   3-day dietary records  X X X X 
Functional status      
  Hand grip strength X X X X X 
  Five-times-sit-to-stand-test  X X X X X 
Psychosocial measures      
  Quality of life  X   X X 
  Self-efficacy X   X X 
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Functional Status 
Hand grip strength 
Hand grip strength was measured in both hands using a Grip-D 
dynamometer (Takei Scientific Instruments Co. Ltd., Japan). Participants were 
asked to sit comfortably with the shoulder adducted and forearm neutrally 
rotated, elbow flexed to 90°.162 The dominant hand was tested first, and three 
successive measurements were taken for each hand.162 The time between the 
trials was about 15 seconds, and an average measurement for both hands was 
used for analysis. Measurably reduced grip strength was defined as the value 
below the average for specific age and gender as supplied by the device 
manufacturer. 
Five-times-sit-to-stand-test 
Participants were asked to sit on a slightly padded armless chair with their 
feet flat on the floor and the back upright against the back rest of the chair.22 
Next, they were asked to fold their upper limbs across the chest and to stand up 
all the way and sit down landing firmly, as fast as possible, 5 times without using 
their arms. Using a stop watch, the test timing began on the command “go” 
(participant sitting), and ceased on landing after the fifth stand up.22 The sit-to-
stand time was recorded to the nearest 0.10 seconds. Individuals with sit-to-
stand-test time exceeding 11.4 seconds in the 50 - 69 year age group and 12.6 
seconds in the 70 - 79 year group were considered having worse than average 
functional performance.163 
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Bioimpedance Analysis (BIA) 
Changes in lean body mass were assessed by bioimpedance analysis at 
each of the five time points using a multiple-frequency device (QuadScan 4000, 
Bodystat Ltd, Douglas, UK). After the participant assumed a supine position, four 
electrodes were placed in the standard tetrapolar arrangement, which involved 
the placement of two electrodes on the hand (one on the bony protuberance that 
forms the wrist, i.e. between the styloid processes of the ulna and radius, and the 
other just behind the metacarpals), and two electrodes on the foot (one on the 
ankle placed midline between the medial and lateral malleoli, and the other just 
behind the metatarsals).55,66 Two measurements were taken at 5 and 10 minutes, 
we have utilized the 10 minute BIA data for our analysis.164 The two primary BIA 
variables of interest were phase angle (PA), quantified as the ratio of the arc 
tangent of reactance to resistance (arc tangent [Xc/R] × [180°/π], measured at 50 
kHz and expressed in degrees); and Impedance Ratio (IR) as the ratio of 
impedance measured at 200 kHz to impedance measured at 5 kHz.154 
Reference values for PA were taken from data generated among the 
American adult population,86 and PA value below the 5th percentile was used as 
an indicator of malnutrition. Additionally, standardized phase angle (SPA) was 
calculated as [(Observed PA – Mean PA)/Standard Deviation (SD)], where mean 
and SD were taken from the reference values.89 A SPA < -1.65 represented the 
10th percentile and was used as a cutoff to indicate malnutrition.165  Although 
reference cut-points have not yet been established as they have for PA, IR 
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values > 0.78 in males and > 0.82 in females were used as cutoffs for 
malnutrition.98 
Statistical Analysis 
The data were analyzed using the SAS software, Version 9.4 (Copyright © 
2013 SAS Institute Inc., Cary, NC, USA). Descriptive statistics were used to 
calculate frequencies, means and standard deviation. One-way repeated 
measures ANOVA was performed to assess changes in total PG-SGA score, 
anthropometric, bioimpedance, functional status, and dietary intake data over 
time. A post-hoc analysis with Bonferroni’s adjustment was done for multiple 
pairwise comparisons over time. A contingency table was used to determine the 
sensitivity, specificity, and predictive values. Fisher’s exact test was used to test 
the differences between the PG-SGA and Consensus ratings at each time-point. 
Independent samples t-test assessed differences for mean PA and IR between 
the Consensus identified malnourished and well-nourished individuals (or PG-
SGA score 0-8 vs. ≥ 9 categories). Simple logistic regression was used to 
analyze the BIA related predictors of malnutrition as defined by the Consensus or 
the PG-SGA criteria [with either the Consensus or the PG-SGA as binary 
outcome variables (0 = not-malnourished, 1 = malnourished)]. Pearson’s 
correlation examined the association between variables. Significance level was 
set at P ≤ 0.05. Figures were constructed using the GraphPad Prism version 6.07 
for Windows, GraphPad Software, La Jolla California USA. 
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Results 
Baseline Characteristics 
Of the19 participants, 18 were male and 1 female; the mean age was 59 ± 
7 years (Table 3-1). The mean BMI was 29 ± 5 kg/m2; 26% were normal weight, 
32% overweight, and 42% were categorized as being obese. Fifteen (79%) 
participants were diagnosed with Stage IV cancer and four (21%) had Stage III 
disease. Most tumors were localized at the oropharynx (58%), followed by the 
oral cavity (16%), larynx (11%) and maxillary sinuses (11%), and paranasal 
sinuses (5%). Thirteen individuals had undergone a tumor resection surgery prior 
to starting their treatment. About 74% were either current or former smokers and 
63% were either current or former alcohol consumers. Only 2 participants had a 
history of smokeless tobacco intake. 
Consensus Diagnostic Criteria 
 Frequency of individuals meeting the malnutrition diagnostic markers as 
outlined by the Consensus is shown in Table 3-2 and Figure 3-2. Seventy-eight 
percent were identified as having reduced grip strength at baseline, while 100% 
had reduced strength during the post-treatment period (T4 and T5). At T3 and 
T4, 88% indicated a loss in muscle mass and up to 94% showed loss in 
subcutaneous fat in this period. At T1 39% and at T3 82% exhibited unintended 
weight loss. 
 Table 3-3 shows the number of characteristic markers met at each time 
point. Two or more of the 6 characteristics were evident, indicating a diagnosis of 
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malnutrition in 67% at T1, 94% at T3, and by all participants during the post-
treatment period. Of the total 84 observations, 76 (90%) met 2 or more of the 6  
characteristic markers. Nine met 5 markers (and of these, all 9 were rated PG-
SGA-B or -C) and 35 met 4 markers (with 34 rated as PG-SGA-B or -C and one -
A). Additional comparison of the two diagnostic approaches will be thoroughly 
presented in a subsequent section. 
PG-SGA Score and Nutrition Impact Symptoms 
The frequency of obtaining a higher PG-SGA score (≥ 9, indicating a 
critical need for improved symptom management and nutrient intervention) and 
the most commonly reported nutrition impact symptoms (NIS) are shown in Table 
3-4. At baseline, 39% scored ≥ 9 in the PG-SGA (score range 2 – 16), while at 
T3, all individuals had a higher score (range 11 – 26). At T4, 81% (range 5 – 20) 
and at T5, 93% (range 3 – 17) had higher PG-SGA scores (Table 3-4). Overall, 
individuals scoring ≥ 9 in the PG-SGA had undergone 11% weight loss in the 
past 6 months and 8% loss in the previous 3 months. 
Problems with eating and swallowing, taste changes, pain, no appetite, 
mouth sores, dry mouth, and nausea were the most commonly reported NIS 
during and after treatment (Table 3-4, Figure 3-3). At baseline, 58% reported 
problems with eating and 28% had problems swallowing. During treatment (T2 
and T3), all participants had problems with eating, and up to 82% reported 
having pain and swallowing issues. At T2, 63% had taste alterations and 47% 
reported having mouth sores and no appetite. At T4, 94% reported problems with 
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eating, 63% problem swallowing, 56% had taste changes, and up to 38% 
reported pain, mouth sores, and appetite loss. At T5, 86% had problems with 
eating, 50% problem swallowing, and 43% reported changes in their taste. 
Table 3-1: Baseline demographic and clinical characteristics of participants 
(n = 19). 
Age (years ± SD) 59 ± 7  
 n % 
Gender   
Male 18 95 
Female 1 5 
Body weight (kg ± SD) 89 ± 21  
Height (cm ± SD) 179 ± 9  
Body mass index (kg/m2 ± SD) 29 ± 5  
Normal (18.5–24.9) 5 26 
   Overweight (25.0–29.9) 6 32 
   Obesity Class I (30.0–34.9) 4 21 
   Obesity Class II (35.0–39.9) 4 21 
TNM Staging†   
   Stage III 4 21 
   Stage IVA 13 68 
   Stage IVB 1 5 
   Stage IVC 1 5 
Primary tumor localization    
Oropharynx 11 58 
Oral cavity 3 16 
Larynx 2 11 
Maxillary sinuses 2 11 
Paranasal sinuses 1 5 
Surgical resection* 13 68 
Tobacco and Alcohol Status   
Smoking   
Current  3 16 
Former  11 58 
None 5 26 
Alcohol   
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Current  9 47 
Former  3 16 
None 7 37 
† Created and updated by the American Joint Committee on Cancer and the International Union 
Against Cancer. TNM system is based on the size and/or extent of the primary tumor (T), the 
amount of spread to nearby lymph nodes (N), and the presence of metastasis (M).166  
*Participants who underwent tumor resection surgery prior to the initiation of chemotherapy and 
radiation therapy. 
 
Table 3-2: Frequency (n,%) of individuals meeting the malnutrition diagnostic 
markers as outlined by the Consensus criteria during each time-point.† 
 Time 1 Time 2 Time 3 Time 4 Time 5 
Characteristic markers n = 18 n = 19 n = 17 n = 16 n = 14 
Inadequate energy intake 5 (28) 9 (47) 3 (18) 2 (13) 8 (57) 
Weight loss 7 (39) 12 (63) 14 (82) 10 (63) 12 (86) 
Loss of muscle mass 10 (56) 13 (68) 15 (88) 14 (88) 12 (86) 
Loss of subcutaneous fat 9 (50) 13 (68) 15 (88) 15 (94) 6 (43) 
Reduced hand grip strength 14 (78) 15 (79) 15 (88) 16 (100) 14 (100) 
Five-times-sit-to-stand-test* 12 (67) 9 (47) 9 (53) 8 (50) 9 (64) 
Edema 0 0 0 2 (13) 1 (7) 
† Per the Consensus criteria, five-times-sit-to-stand-test (FTSST) is not the usual 
recommendation for assessing reduced functional status; and is included in this table to allow for 
comparisons with reduced hand grip strength. 
* Individuals with an inability to perform FTSST due to muscle weakness or excess body weight 
making it difficult to perform the test are included in this count (excluding individuals who declined 
to perform the test due to reasons such as surgery in leg, and pain, fever, nausea, drowsiness, 
and tiredness due to ongoing treatment.). 
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Figure 3-2: Number of participants meeting the malnutrition diagnostic markers as 
outlined by the Consensus criteria during each time-point. 
 
 
Table 3-3: Number of Consensus characteristic markers met at each time 
point. 
Number of markers Time 1 Time 2 Time 3 Time 4 Time 5 Total 
 n=18 n=19 n=17 n=16 n=14  
0 1 0 0 0 0 1 
1 5 1 1 0 0 7 
2 2 4 1 2 0 9 
3 5 5 5 2 6 23 
4 4 7 7 11 6 35 
5 1 2 3 1 2 9 
2 or more met†, n (%) 12 (67) 18 (95) 16 (94) 16 (100) 14 (100) 76 (90) 
† Per the Consensus criteria, meeting at least 2 out of the 6 characteristic markers indicates a 
diagnosis of malnutrition. 
 
 
 
 
R
e
d
u
c
e
d
 g
r i
p
 s
tr
e
n
g
th
L
o
s
s
 o
f  
m
u
s
c
le
 m
a
s
s
L
o
s
s
 o
f  
s
u
b
c
u
ta
n
e
o
u
s
 f
a
t
W
e
ig
h
t  
lo
s
s
In
a
d
e
q
u
a
te
 e
n
e
rg
y
 i
n
ta
k
e
0
2 0
4 0
6 0
8 0
F
r
e
q
u
e
n
c
y
 (
n
)
T1
T2
T3
T4
T5
 74 
 
Table 3-4: Frequency (n,%) of PG-SGA score ≥ 9 and most commonly 
reported nutrition impact symptoms across time. 
 Time 1 Time 2 Time 3 Time 4 Time 5 
 n = 19 n = 19 n = 17 n = 16 n = 14 
PG-SGA score ≥ 9 7 (39) 18 (95) 17 (100) 13 (81) 13 (93) 
Nutritional impact symptoms*      
No problem eating 8 (42) 0 0 1 (6) 2 (14) 
Problem swallowing 5 (28) 14 (74) 14 (82) 10 (63) 7 (50) 
Taste changes 2 (11) 12 (63) 7 (41) 9 (56) 6 (43) 
Pain 3 (17) 10 (53) 14 (82) 6 (38) 3 (21) 
No appetite 2 (11) 9 (47) 7 (41) 6 (38) 5 (36) 
Mouth sores 0 9 (47) 10 (59) 6 (38) 0 
Dry mouth 3 (17) 8 (42) 4 (23) 5 (31) 7 (50) 
Nausea 0 5 (26) 6 (35) 2 (13) 2 (14) 
*Participants could select multiple symptoms in the PG-SGA form. 
Abbreviation: PG-SGA, Patient-Generated Subjective Global Assessment 
 
 
 
 
 
Figure 3-3: Frequency of commonly reported nutrition impact symptoms in 
the PG-SGA during and after treatment. 
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Comparison of the Consensus Diagnostic Criteria with the PG-SGA 
The frequency of PG-SGA ratings and the Consensus criteria is presented 
in Table 3-5. At each time point, no significant differences in ratings were found 
between the two measures (Fisher’s exact test P > 0.05). At T1, the PG-SGA 
rated 13 (68%), while the Consensus diagnosed 12 (67%) individuals with 
malnutrition. From T2 through T4, only one participant was found well-nourished 
by the PG-SGA, while the Consensus found 2 well-nourished individuals in this 
period. At T5, the PG-SGA rated 13 (93%) while the Consensus criteria rated 14 
(100%) individuals with malnutrition. Significant differences were found between 
the mean PG-SGA scores for the three categories of Consensus criteria (P < 
0.0001) (Figure 3-4). 
Of the total 84 observations, 72 (86%) were correctly classified by the 
Consensus criteria as being malnourished (true positives) and 3 (4%) were 
correctly classified as well-nourished (true negatives) (Table 3-6). Four (5%) 
observations were misclassified by the Consensus as being malnourished (false 
positives), and 5 (6%) were misclassified as well-nourished (false negatives). 
The sensitivity of the Consensus criteria was 94% with a positive predictive value 
of 95%; specificity was 43% with a negative predictive value of 37%. 
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Table 3-5: Nutritional status ratings by PG-SGA and the Consensus 
diagnostic criteria across time. 
      
 Time 1 Time 2 Time 3 Time 4 Time 5 
      
Scored PG-SGA Global Assessment n=19 n=19 n=17 n=16 n=14 
Well-nourished (SGA-A) 6 (32) 0 0 0 1 (7) 
Moderate or suspected malnutrition  (SGA-B) 11 (58) 16 (84) 9 (53) 12 (75) 10 (71) 
Severely malnourished (SGA-C) 2 (11) 3 (16) 8 (47) 4 (25) 3 (21) 
      
Consensus Diagnosis n=18* n=19 n=17 n=16 n=14 
Well-nourished 6 (33) 1 (5) 1 (6) 0 0 
Nonsevere (Moderate) Malnutrition 11 (61) 12 (63) 12 (71) 16 (100) 7 (50) 
Severe Malnutrition 1 (6) 6 (32) 4 (23) 0 7 (50) 
 *Missing, n=1 
Abbreviation: PG-SGA, Patient-Generated Subjective Global Assessment 
 
 
Table 3-6: Sensitivity and specificity of the Consensus diagnostic criteria 
(over all observations including all time-points, n = 84). 
 
PG-SGA Malnourished 
(B or C) 
PG-SGA Well-nourished 
(A) 
Consensus Malnourished 72 (86%) True positive* 4 (5%) False positive 
Consensus Well-nourished 5 (6%)  False negative 3 (4%) True negative† 
 
*Sensitivity, or the ability of the Consensus to correctly identify individuals with 
malnutrition was 94%. Positive predictive value, or the likelihood that individuals with 
Consensus diagnosed malnutrition were truly malnourished was 95%. 
†Specificity, or the ability of the Consensus to correctly identify individuals with no 
malnutrition was 43%. Negative predictive value, or the likelihood that individuals with 
Consensus categorized well-nourished were truly not malnourished, was 37%. 
Abbreviation: PG-SGA, Patient-Generated Subjective Global Assessment 
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Figure 3-4: Overall comparison of the PG-SGA scores according to the 
Consensus diagnostic criteria (over all observations including all time-
points, n = 84). 
 
 
*** P < 0.001 compared to well-nourished, P < 0.01 compared to moderate malnutrition. 
** P = 0.01 compared to well-nourished. 
Values are means ± standard deviation. 
Abbreviation: PG-SGA, Patient-Generated Subjective Global Assessment 
 
Changes in the PG-SGA Score, Anthropometric, BIA, and Functional Status 
Markers 
Compared to the baseline, a significant increase in the total PG-SGA 
score was noted from T2 through T5 (Table 3-8). Significant decreases in the 
absolute body weight and BMI were observed between T1 and the other time-
points (P ≤ 0.0001) (Table 3-8, Figure 3-5). At T1, 71% of all participants had lost 
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some weight. At T3, mean weight loss of 11% over the past 3 months was 
observed (Figure 3-5). The PG-SGA score was significantly correlated with BMI 
(r = -0.23, P = 0.032) and percent weight loss 6 months ago (r = 0.34, P = 0.004). 
The correlation between hand grip strength and the PG-SGA score did not reach 
statistical significance (r = -0.19, P = 0.085). 
No changes in the TSF measurements were observed over time, while 
mean MUAC significantly decreased from mid-treatment (T2) to the post-
treatment period (T4 and T5) (P ≤ 0.001). No significant differences were found 
in the mean TSF (P = 0.337) or MUAC (P = 0.807) measurements between the 
Consensus identified malnourished and well-nourished individuals. 
Mean PA significantly decreased from baseline to the end of treatment (T1 
- T3) and post-treatment period (T1 - T4, T1- T5) (P < 0.05). A significant 
increase in the mean IR was observed from baseline to the end of treatment (T1 
– T3) (P <0.05) and post-treatment periods (T1 – T4, T1 – T5) (P ≤ 0.01). 
Hand grip strength decreased between the baseline and one month post-
treatment period (T1 - T4) (P < 0.01). Hand grip strength was significantly 
correlated with sit-to-stand-test time (r = - 0.37, P = 0.002). Although the sit-to-
stand time increased from T1 through T3, this change was not found to be 
significant. 
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Changes in Dietary Intake and Nutrition Support (NS) 
Significantly fewer calories and protein (gm/kg body weight) were 
consumed during treatment (T2) compared to the post-treatment period (T4) (P < 
0.01) (Table 3-9). At the end of treatment, 15 of 17 participants (88%) were using 
enteral NS, and 75% of the total calories and 80% of the total protein intake was 
provided through NS. One month post-treatment, 12 of 16 individuals (75%) were 
on enteral feedings, and 66% of the total caloric and 68% of the total protein 
needs were met through NS.  
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Table 3-7: Anthropometric, bioimpedance, and functional status data across time. 
 Time 1 Time 2 Time 3 Time 4 Time 5 P-value† 
 n = 19 n = 19 n = 17 n = 16 n = 14  
Total PG-SGA Score 8 ± 4 15 ± 5 17 ± 5 13 ± 4 12 ± 4 <0.0001a 
Anthropometry 
Body weight (kg) 93 ± 23 90 ± 22 88 ± 21 86 ± 20 88 ± 21 0.0001b 
Body mass index (kg/m2) 29  ± 5 28  ± 5 27 ± 5 27  ± 4 27  ± 5 <0.0001c 
Triceps skinfolds (mm) 13  ± 6 13  ± 6 12  ± 7 13  ± 7 13  ± 5 0.522 
Mid-upper-arm circumference (cm) 30  ± 5 34  ± 4 33  ± 5 29  ± 3 29  ± 3 0.0001d 
Bioimpedance 
Phase angle (50 kHz) 5.56  ± 0.79 5.5  ± 0.9 5.13  ± 0.85 5.0  ± 0.8 5.14  ± 0.71 0.0023e 
Impedance ratio (200 kHz/5 kHz) 0.81  ± 0.02 0.81  ± 0.03 0.82  ± 0.03 0.82  ± 0.03 0.82  ± 0.03 0.0015f 
Functional status 
Hand grip strength (kg) 32  ± 8 32  ± 9 31  ± 8 31  ± 6 30  ± 6 0.0031g 
Five-times-sit-to-stand test (sec) 13  ± 4 13  ± 4 15  ± 7 13  ± 4 13  ± 3 0.1763 
Values are means ± standard deviation. 
†Analyzed by one-way repeated measures ANOVA. 
a-g Per the Bonferroni post-hoc test, pairwise comparisons (adjusted P values): 
a P ≤ 0.0001  for T1 – T2 and T1 – T3; P < 0.05 for T1 – T4 and T1 – T5. 
b,c P ≤ 0.0001 for T1 – T2, T1 – T3, T1 – T4, and T1 – T5; P < 0.001 for T2 – T3, T2 – T4, and T2 – T5; and P <0.05 for T3 – T5. 
d P ≤ 0.001 for T2 – T4 and T2 – T5 and P <0.05 for T3 – T5. 
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e P < 0.05 for T1 – T3, T1 – T5, T2 – T3; P < 0.01 for and T1 – T4 and T2 – T4. 
f P < 0.005 T1 – T4, T2 – T3, and T2 – T4; P < 0.05 for T1 – T3, and T1 – T5. 
g P < 0.01 for T1 – T4; P < 0.05 for T2 – T4. 
Abbreviation: PG-SGA, Patient-Generated Subjective Global Assessment 
 
 
Figure 3-5: Mean body weight and percent weight loss over the previous 3 months† across time. 
 
 
 
 
 
†3 months ago body-weights were obtained from medical record review when patients were visiting the clinic and nurses 
took patients’ weights during routine clinic assessment. 
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Table 3-8: Changes in total caloric and protein intake and Enteral Nutrition Support (ENS) across time. 
 Time 1 Time 2 Time 3 Time 4 Time 5 P-value
† 
Total intake (Diet + ENS) n = 19 n = 19 n = 17 n = 16 n = 14  
Energy (kcal) 2058  ± 687 1822  ± 293 2150  ± 459 2265  ± 399 1805  ± 582 0.001a 
Energy (kcal/kg) 23  ± 9 21  ± 6 26  ± 8 27  ± 7 22  ± 11 0.001b 
% Estimated energy needs 94  ± 41 84  ± 28 100  ± 35 103  ± 34 76  ± 29 0.001 
Protein (gm) 85  ± 32 72 ± 17 90  ± 20 94  ± 19 70  ± 20 0.002c 
Protein (gm/kg) 0.9  ± 0.4 0.9  ± 0.3 1.0  ± 0.3 1.1  ± 0.3 0.9  ± 0.3 0.001d 
       
Enteral nutrition support n = 2 n = 7 n = 15 n = 12 n = 6  
Energy (kcal) 208 ± 620 546 ± 749 1630 ± 769 1521 ± 996 587 ± 876 <.0001e 
Protein (gm) 9 ± 28 24 ± 33 72 ± 35 67 ± 44 26 ± 39 <.0001f 
% Energy intake of total 10 ± 28 29 ± 40 75  ± 33 66  ± 42 28  ± 41 <.0001g 
% Estimated energy needs 13  ± 38 27  ± 41 76  ± 47 70  ± 54 25  ± 37 <.0001h 
% Protein intake of total 10 ± 31 31 ± 43 80  ± 33 68  ± 43 30  ± 44 <.0001i 
Values are means ± standard deviation. 
†Analyzed by one-way repeated measures ANOVA. 
a-i Per the Bonferroni post-hoc test, pairwise comparisons (adjusted P values): 
a- d P ≤ 0.01 for T2 – T4. 
e-i P < 0.0001 for T1 – T3, T1 – T4; and P ≤ 0.001 for T2 –T3.
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Bioimpedance Analysis (BIA): Malnutrition and Functional Status 
Outcomes 
PA was significantly lower among the Consensus categorized 
malnourished individuals than those who were well-nourished (P = 0.019) (Table 
3-9). Individuals with a PG-SGA score ≥ 9 had a lower PA than those with < 9 
PG-SGA score (P = 0.023) (Table 3-10). IR was significantly higher among 
Consensus diagnosed malnourished individuals than those categorized as well-
nourished (P = 0.013); and those with PG-SGA score ≥ 9 had a higher IR than 
those scoring < 9 (P = 0.022). 
Overall, 63% were correctly identified by the SPA as being malnourished 
(true positives) and 5% were correctly classified as well-nourished (true 
negatives) (Table 3-11). The sensitivity of the SPA was 68% with a positive 
predictive value of 96%; specificity was 67% with a negative predictive value of 
14%. Significant differences in the mean PG-SGA score were found between 
SPA identified malnourished (14.3 ± 4.7) and well-nourished (11.5 ± 5.6) 
individuals (P = 0.016). Simple logistic regression showed that SPA was a 
significant predictor of malnutrition when defined by the Consensus criteria (P = 
0.014), but not with the PG-SGA rating criteria (P = 0.133). Similarly, IR was a 
significant predictor of malnutrition when defined by the Consensus (P = 0.04), 
but not when using the PG-SGA rating criteria (P = 0.851). 
Overall, the PG-SGA score was significantly correlated with PA (r = -0.35, 
p = 0.002), SPA (r = -0.34, P = 0.002), and IR (r = 0.36, P = 0.001) (see Figure 3-
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6 and 3-7). Hand grip strength was correlated with PA (r = 0.48, P < 0.001), SPA 
(r = 0.35, P = 0.001), and IR (r = -0.47, P < 0.0001) (see Figure 3-8 and 3-9). Sit-
to-stand-test time was correlated with IR (r = 0.30, P = 0.014) and PA (r = -0.34, 
P = 0.005) but not with the SPA (r = -0.19, P = 0.124). 
Table 3-9: Phase angle and impedance ratio among the Consensus categorized 
malnourished and well-nourished individuals. 
 Consensus Well-nourished Consensus Malnourished P - value 
Phase angle 5.9 ± 0.67 (4.5 - 6.6) 5.2 ± 0.84 (3.0 - 7.1) 0.019 
Impedance ratio 0.80 ± 0.02 (0.78 - 0.83) 0.82 ± 0.03 (0.75 - 0.89) 0.013 
Values are means ± standard deviation (range). 
 
Table 3-10: Phase angle and impedance ratio among the PG-SGA score 
categories. 
 
Not at nutrition risk 
(PG-SGA score 0-8) 
At nutrition risk 
(PG-SGA score ≥ 9) 
P - value 
Phase angle 5.7 ± 0.77 (4.4 - 7.1) 5.2 ± 0.83 (3.0 - 7.1) 0.023 
Impedance ratio 0.80 ± 0.02 (0.76 - 0.85) 0.82 ± 0.03 (0.75 - 0.89) 0.022 
Values are means ± standard deviation (range). 
Abbreviation: PG-SGA, Patient-Generated Subjective Global Assessment 
 
Table 3-11: Sensitivity and specificity of the SPA over all observations including 
all time-points (n = 83). 
 
PG-SGA Malnourished 
(B or C) 
PG-SGA Well-nourished 
(A) 
SPA Malnourished 52 (63%) True positive* 2 (2%) False positive 
SPA Well-nourished 25 (30%)  False negative 4 (5%) True negative† 
 
*Sensitivity, or the ability of the SPA to correctly identify individuals with malnutrition 
was 68%. Positive predictive value, or the likelihood that individuals with SPA 
identified malnutrition were truly malnourished was 96%. 
†Specificity, or the ability of the SPA to correctly identify individuals with no malnutrition 
was 67%. Negative predictive value, or the likelihood that individuals who were SPA 
identified well-nourished were truly not malnourished, was 14%. 
Abbreviation: PG-SGA, Patient-Generated Subjective Global Assessment. SPA, 
Standardized Phase Angle. 
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Figure 3-6: Pearson’s correlation between the PG-SGA score and phase angle 
over all observations including all time-points (n = 84). 
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Figure 3-7: Pearson’s correlation between the PG-SGA score and impedance ratio 
over all observations including all time-points (n = 84). 
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Figure 3-8: Pearson’s correlation between the hand grip strength and phase angle 
over all observations including all time-points (n = 84). 
 
4 6 8
1 0
2 0
3 0
4 0
5 0
6 0
P h a s e  a n g le  ( )
H
a
n
d
 g
r
ip
 s
tr
e
n
g
th
 (
k
g
)
r  =  0 .4 8 , P  <  0 .0 0 1
 
 
 
 
Figure 3-9: Pearson’s correlation between the hand grip strength and impedance 
ratio over all observations including all time-points (n = 84). 
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Discussion 
To our knowledge, this is the first study that has longitudinally investigated 
nutritional status outcomes among individuals with HNC in an outpatient setting 
using the recent Academy/A.S.P.E.N. Consensus malnutrition diagnostic criteria. 
Our results indicate that individuals with HNC are malnourished even before 
treatment initiation. Using the Consensus criteria, 67% of our participants were 
malnourished before treatment; and the prevalence of malnutrition consistently 
increased during treatment and the post-treatment period. Significant weight loss 
was exhibited by nearly 40% of our participants before treatment; and loss in 
weight continued up to 3 months after treatment was completed for 86% of the 
participants. Problems with eating, dry mouth, taste changes, and difficulty 
swallowing were the commonly reported nutrition impact symptoms even 3 
months after treatment completion, likely contributing to inadequate dietary intake 
and resulting in unintended weight loss and loss of lean tissue. The mean triceps 
skinfolds (TSF) measurement did not change over time; and while the mean mid-
upper-arm circumference (MUAC) decreased after treatment, no changes in 
MUAC were observed during treatment. Additionally, no differences in the mean 
TSF or MUAC measurements were found between the Consensus identified 
malnourished and well-nourished individuals. Therefore, despite significant 
losses in the absolute body weight and the loss of body fat and muscle mass 
identified by the nutrition-focused physical exam, anthropometric measures such 
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as TSF and MUAC seemed less sensitive to identify malnutrition or changes in 
the lean tissue over time. 
Comparing the Two Malnutrition Diagnosis Approaches – Scored PG-SGA 
and the Consensus Criteria 
Our results indicate that compared to our chosen reference standard PG-
SGA, the Consensus criteria identified malnutrition with overall good sensitivity 
(95%) and specificity (43%). A higher sensitivity indicates that the Consensus 
was correctly categorizing individuals with actual malnutrition; which takes 
precedence over specificity, or correctly classifying individuals with no 
malnutrition. Longitudinally, no significant differences between the ratings of 
these two measures were observed; and both reported increases in the 
prevalence of malnutrition from the beginning of treatment to up to 3 months after 
treatment completion. Individuals who met the Consensus definition for 
malnutrition were more likely to be rated malnourished using the PG-SGA 
assessment. 
That said, some functional differences between the two assessment 
approaches needs discussion. The PG-SGA calculates an overall numerical 
score that can possibly be used to cater immediate symptom management 
and/or nutritional intervention strategies.161 Statistically speaking, unlike the three 
Consensus categories (well-nourished, or moderate or severe malnutrition) the 
PG-SGA score is a continuous variable against which other nutritional 
parameters can be validated. For instance, we found that individuals with ≥ 9 PG-
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SGA score had also lost 11% of their absolute body weight in the past 6 months. 
Furthermore, about 40% of our participants were in critical need of nutrition 
intervention before treatment initiation as indicated by a PG-SGA score ≥ 9. 
Agreeably, significant differences were also observed between the mean PG-
SGA scores for the three Consensus categories, and malnourished individuals 
had a higher score than those categorized as well-nourished. 
The PG-SGA also offers the feature of selecting various nutrition impact 
symptoms (NIS) that affect oral intake. While some researchers have 
administered the PG-SGA in the HNC setting once; either before or during 
treatment,167,168 this longitudinal study gathered NIS data before, during, and 
after treatment completion. Problems with eating and swallowing, taste changes, 
pain, and mouth sores were among the most commonly reported NIS during 
treatment. Usually, most symptoms that affect intake are expected to resolve 
soon after treatment completion, however we noted that even 3 months after 
treatment, 86% continued to have problems with eating, and dry mouth, taste 
changes, and difficulty swallowing were among the commonly reported 
symptoms. It has been reported that many individuals with HNC become 
malnourished after treatment as a result of treatment-induced weight loss, loss of 
appetite, taste changes, and reduced oral intake.169 Not surprisingly in our study, 
all participants met the Consensus malnutrition criteria at 1 month and 3 months 
after treatment completion, suggesting poor nutritional and functional status 
outcomes months after treatment completion. In the future, knowing the 
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prevalence of NIS could be useful while considering patient-specific interventions 
that could potentially help with the timely management of unintended weight loss 
and reduced dietary intake.170 
While the PG-SGA calculates a numerical score and specifies symptoms 
that affect oral intake, its capacity to evaluate dietary and functional status 
related data is fairly limited. For example, dietary intake and functional status is 
assessed primarily through two subjective questions in the PG-SGA history 
section that are self-reported by the participant. On the other hand, the 
Consensus characteristic for insufficient energy intake is gathered through 
dietary assessment methodologies such as 24-hour recall, diet history, or in the 
case of nutrition support (NS), through intake and output records.157 In our study, 
at the end of treatment 18% of the participants met the Consensus criterion of 
inadequate energy intake. Importantly, 15 out of 17 individuals were actively 
using enteral NS at the end of treatment, and 75% of the total caloric and 80% of 
the total protein requirements were met through enteral feedings. Earlier, the use 
of enteral NS in HNC setting has been shown to prevent weight loss, 
malnutrition, dehydration, and treatment interruptions.171 A gastrostomy tube was 
placed in 18 of our participants before treatment initiation, and NS was crucial 
during and immediately after treatment completion when symptoms such as pain, 
mouth sores, taste changes, and problems swallowing made oral intake quite 
challenging. Clearly, the Consensus characteristic for assessing inadequate 
intake takes a comprehensive approach while gathering oral and/or NS related 
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data. It is important to note that currently there is a lack of consensus on 
estimating energy requirements in the HNC patient population, and this study 
used the kcal/kg body weight method using the European Society for Clinical 
Nutrition and Metabolism guidelines (2006).159 For example, using these 
guidelines we found that at Time 1, 7/19 individuals were meeting their energy 
needs, but of these, four individuals still experienced moderate to severe weight 
loss at Time 2. Estimated energy requirements calculated by another method (for 
example, Mifflin St. Jeor equation) could possibly yield differences in energy 
estimation and interpretation of the ‘insufficient energy intake’ marker for the 
Consensus criteria. Therefore, additional studies are needed for establishing 
evidence-based nutrient recommendations for the ambulatory oncology patient 
population. 
The Consensus recommends the use of hand grip strength as an 
objective marker of performance status. Among individuals with HNC, reduced 
grip strength has been associated with a higher risk for mortality and 
postoperative complications.172,173 Moreover, chronic inflammation, skeletal 
muscle catabolism, poor nutritional intake, and sedentary behavior during HNC 
treatment often results in loss of protein and lean muscle mass stores.8,20 
Seventy-eight percent of our participants were identified to have reduced grip 
strength before treatment initiation, and all had reduced strength after treatment 
completion. Jager-Wittenar et al169 noted that although grip strength showed 
improvements 4 months after HNC treatment completion, no improvements in 
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lean muscle mass were noted as measured by dual-energy X-ray 
absorptiometry. In our study, the mean grip strength was significantly lower after 
treatment completion when compared to during treatment, and those with lower 
grip strength also had a lower PA and higher IR, suggesting that a loss of lean 
tissue mass was associated with impaired muscle function and strength. 
Individuals with a reduced grip strength had higher five-times-sit-to-stand-
test (FTSST), and a higher FTSST also correlated with a low PA and higher IR. 
However, unlike the grip strength test, some individuals declined to perform the 
FTSST due to various reasons such as muscle weakness, and treatment induced 
pain, fever, nausea, drowsiness, and tiredness making it difficult to rise and sit 
down five times from a chair. Therefore based on our observation, FTSST might 
not be a feasible measure of performance status among individuals actively 
undergoing chemoradiation treatment.  
BIA Parameters and Malnutrition Outcomes 
Our results indicated a lower PA and higher IR among individuals with ≥ 9 
PG-SGA scores than those with lower scores; suggesting the utility of BIA 
parameters in detecting poor nutritional status. In the past, limited research has 
suggested PA108 and IR63 to be valid parameters for identifying malnutrition 
among hospitalized inpatients. Among individuals with advanced colorectal 
cancer, Gupta and colleagues have found that the subjective global assessment 
(SGA) classified well-nourished individuals had a significantly higher median PA 
score (6.12) than those who were malnourished (5.18).115 We observed similar 
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findings using the Consensus criteria; malnourished HNC individuals had a lower 
mean PA (5.2 vs. 5.9) and higher IR (0.82 vs. 0.80) than those classified as well-
nourished. 
Recent (and limited) observations have indicated that the standardization 
of phase angle by creating z-scores per the reference values adjusted for age, 
gender, and BMI, known as the SPA is a more reliable indicator of nutritional and 
functional status than the absolute PA value.174 In a heterogeneous sample of 
individuals with various malignancies (n = 399, including HNC), SPA was found 
to be an independent predictor for malnutrition, impaired functional status, and 
six-month survival.89 Our results indicated that individuals identified as 
malnourished using the SPA cut-off had significantly lower PG-SGA score than 
well-nourished ones and overall, the SPA identified malnutrition with good 
sensitivity (68%) and specificity (67%). We also found that SPA and IR were 
significant predictors of malnutrition when defined by the Consensus criteria, but 
not using the PG-SGA criteria. A possible explanation for this observation could 
be that the Consensus criteria requires a comprehensive assessment of 
malnutrition with more objective assessment parameters compared to the PG-
SGA; and was therefore detected through the BIA. 
Taken together, our results indicate that the BIA parameters PA, SPA, and 
IR might be useful in identifying individuals who are at increased risk for 
malnutrition, and can possibly be incorporated in the outpatient clinical setting as 
prognostic indicators of malnutrition. Thus in situations where simple measures 
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such as body weight and BMI might not be reliable indicators of body 
composition, the diagnosis of malnutrition may be improved by incorporating 
feasible bioimpedance measures that can be used to assess changes in lean 
tissue over time. However, additional research is certainly warranted to 
investigate the utility of PA and IR in identifying malnutrition using the Consensus 
framework. 
Limitations and Conclusion 
This study has some limitations that should be noted. First, the elements 
of the nutrition-focused physical exam that assess the loss of muscle and fat 
along with edema are similar to both the Consensus malnutrition diagnostic 
framework and the PG-SGA tool. Therefore, there is a lack of complete 
independence between the subjective elements of the two diagnostic 
approaches, which also makes their comparison difficult. Second, the subjective 
evaluation of muscle and fat loss is often challenging and is prone to inter-
observer error; in this study, the nutrition-focused physical exam was conducted 
by one researcher and thus inter-observer error was not evaluated. Therefore in 
clinical practice and research, physical assessment should be conducted by 
more than one dietitian in order to evaluate reliability and to confirm exam 
findings. A third limitation is that from a field research perspective it was not 
feasible in this study to incorporate a reference method such as the DXA or CT 
imaging for comparisons of subjective evaluation of muscle and fat stores, given 
the constraints of time, space, and patient burden in the CRT outpatient setting. 
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Fourth, the validity and interpretation of apparent loss of muscle tissue is further 
complicated by the possibility that some individuals might have a below normal 
muscle mass but have not actually lost mass; in these instances erroneous 
interpretation of low muscle mass as malnutrition could result. Fifth, the 
longitudinal design of this investigation along with the inclusion of individuals with 
advanced head and neck cancers made it challenging to recruit and enroll a 
larger number of participants. Sixth, with most of our participants being males 
and all Caucasian in descent, our study sample was not heterogeneous in terms 
of gender and ethnicity and thus the results may not be generalizable. Finally, 
given that some data were collected during treatment, it is likely that some 
participants could have felt burdened and did not fully engage with the study 
procedures during this period. Given these limitations and the single center site 
for our data collection, additional research with a heterogeneous and larger 
sample that is conducted in other oncology treatment centers could validate our 
findings. 
Despite these limitations, this study is novel and is the first one to 
longitudinally incorporate the new Consensus framework in the diagnosis of 
malnutrition among the vulnerable HNC population. Notably, compared to the 
PG-SGA, the Consensus criteria involves in-depth data collection and 
comprehensive nutrition assessment parameters. For clinicians, it is also worth 
noting that the scoring of the PG-SGA tool and the identification of the 6 
Consensus markers require time and training. Nevertheless, if clinicians are 
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trained to assess malnutrition diagnostic markers before individuals with cancer 
undergo aggressive treatments, nutritional interventions could be initiated at an 
earlier time and loss in weight and/or lean tissue can be prevented. As we found, 
individuals with HNC do not regain their pre-treatment body weight and are at an 
increased risk for nutritional complications during and after treatment completion. 
That said, timely screening and early detection of malnutrition is a collaborative 
effort between dietitians, physicians, nurses, and other members of the 
healthcare team.3,157 Therefore, dietitian training is needed to identify the 
malnutrition diagnostic characteristics, who could then work collaboratively with 
the physician team for standardization of malnutrition coding practices in medical 
record documentation. Such practices would help with timely identification of 
malnutrition and subsequent implementation of intervention strategies.157 
Based on our results, the use of raw bioimpedance parameters such as 
PA and IR to identify individuals who are at increased risk for malnutrition and/or 
impaired functional status seems promising. However, given that this was a small 
homogenous sample of HNC, additional research is certainly warranted to 
investigate the broader clinical utility of BIA in detecting malnutrition using the 
new Consensus framework in other clinical populations. Research is also needed 
to further validate the Consensus criteria in hospital and ambulatory care 
settings, and to investigate the impact of early nutrition interventions for 
malnutrition in cancer.  
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CHAPTER 4: MALNUTRITION AND ITS ROLE IN QUALITY OF LIFE AND 
COPING SELF-EFFICACY AMONG INDIVIDUALS WITH ADVANCED HEAD 
AND NECK CANCER. 
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Introduction 
Malnutrition, generally defined as a decline in lean body mass with 
functional impairment,3 is highly prevalent among individuals with HNC, with up 
to 40% - 57% having a compromised nutritional status even before beginning 
their treatment.1,11 Malnutrition in HNC has been associated with poor survival 
outcomes and increased morbidity including post-surgical complications, risk of 
infections, impaired wound healing and recovery, and poor functional status.1,8,11–
15 Additionally, HNC disease related symptoms and intensive treatment regimens 
can negatively affect the basic functions of living such as respiration, speech, 
hearing, social eating (e.g., enjoying meals with family and friends), chewing, and 
swallowing.8,9 
Health-related quality of life (QoL) takes a subjective and multidimensional 
approach to assessment that translates an individual’s experience regarding their 
psychosocial well-being, functional status, and disease- and treatment-related 
symptoms.175,176 Therefore, QoL is an important parameter to assess among 
individuals with cancer during various phases of their treatment. Importantly, 
malnutrition has been associated with poor QoL outcomes in cancer, and it has 
been suggested that management of malnutrition may improve QoL for 
individuals with cancer and their caregivers and families.175 However, limited 
research has investigated the relationship between malnutrition and QOL in the 
HNC setting; most research has been conducted elsewhere (Italy, The 
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Netherlands, Sweden, Portugal)32–35,177 involving participants with various 
disease stages and treatment modalities and such data are lacking in the US. 
Self-efficacy theory posits that the greater an individual’s confidence in 
their ability to execute a course of action, the higher the probability that a desired 
goal will be attained.38 Coping self-efficacy is a form of self-efficacy that reflects 
an individual’s belief in their ability to negotiate particular stressors or obstacles 
in their life.178 Receiving a cancer diagnosis and undergoing aggressive 
treatments can negatively affect an individual’s self-efficacy to cope with stress 
and threaten their psychosocial well-being and QoL.10 Previous oncology 
research has indicated that those with higher coping self-efficacy report better 
QoL, may live longer, feel less depressed, participate in treatment decision 
making, and exhibit  fewer illness-related symptoms compared to those who are 
less efficacious in coping.10,36–40 To date, research investigating self-efficacy 
perceptions among individuals with HNC is limited, particularly in the context of 
nutritional outcomes. 
Therefore, the purpose of this study was to evaluate whether QoL and 
coping self-efficacy relate with malnutrition and to investigate the association 
between the QoL and functional status outcomes among advanced HNC 
outpatients. We also assessed longitudinal changes in the QoL and coping self-
efficacy perceptions before and up to 3 months after treatment completion. 
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Methods 
Study Participants and Time-points 
Nineteen individuals with HNC intending to undergo treatment with 
chemoradiotherapy (CRT) at the Masonic Cancer Clinic and Radiation Oncology 
Clinic at the University of Minnesota Medical Center, Fairview were included in 
this study. Quality of life and self-efficacy measures were administered during the 
following three time-points: Time 1 (T1), within 7 days prior to starting the CRT; 
Time 2 (T2), 1 month after the completion of treatment ± 14 days; and Time 3 
(T3), 3 months after treatment completion ± 1 month. Information regarding 
clinical psychological diagnosis was collected through medical record review. 
Data were collected over a total of 47 independent visits. Four participants 
missed one visit and 3 missed two visits. Reasons for absence were changes in 
the treatment plan for three individuals, death in two cases, and declining to 
participate in another two cases. 
Quality of Life and Coping Self-efficacy Assessment 
The European Organization for Research and Treatment of Cancer (EORTC) 
Quality of Life Questionnaire (QLQ): QLQ -C30 and -H&N35 
The EORTC QLQ-C30 (version 3.0) consists of one global health status 
(global QoL) scale and 5 multi-item functional scales that measure physical, role, 
emotional, cognitive, and social functioning. Three multi-item symptom scales 
measure fatigue, nausea and vomiting, and pain, and six single-item symptom 
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scales measure dyspnea, insomnia, appetite loss, constipation, diarrhea, and 
financial difficulties (Appendix D).  
Using the standard scoring procedures outlined by the EORTC Quality of 
Life Group,179 each scale and single-item was scored from 0 - 100. Higher scores 
in the global QoL and functional scales imply higher levels of global QoL or 
functioning; but higher scores in the symptom scales (or single items) indicate 
higher levels (or worsening) of symptoms.180  
The EORTC QLQ-C30 was supplemented with the head and neck cancer 
specific module, QLQ-H&N35180 in order to assess disease- and treatment-
related symptoms common among individuals with HNC. Previously, QLQ-
H&N35 has been used among HNC individuals varying in their disease stages 
and/or treatment modalities.9,33,181–183 The QLQ-H&N35 module comprises a total 
of 35 questions incorporating 7 multi-item scales that assess pain, swallowing, 
sense of taste and smell, speech, social eating, social contact, and sexual 
function; and 11 single-items that assess other symptoms (see Appendix D).  
Since the QLQ-H&N35 questionnaire does not include items that assess 
chewing-related problems, the following three questions were added to the 
module:33 1) How much difficulty did you experience while eating solid food (like 
meat/hard bread)? 2) How much difficulty did you experience while eating dry 
food (like cookies)? 3) How much difficulty did you experience while eating soft 
food (like soft bread)?  
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The QLQ-H&N35 items and scales were scored from 0 - 100, and higher 
scores indicated worsening symptoms.179,180 The chewing-related symptom scale 
was also assessed using the EORTC guidelines.179 The EORTC QLQ-C30 in 
conjunction with QLQ-H&N35 have been shown to be reliable and valid 
measures for assessing QoL among individuals with HNC from various 
countries.180 As expected, most participants in our study were able to complete 
the EORTC questionnaires between 10 and 15 minutes.180 
Cancer Behavior Inventory-Brief Version (CBI-B) 
Self-efficacy for coping with cancer was measured using the Cancer 
Behavior Inventory-Brief Version (CBI-B), a 12-item unidimensional instrument 
(See Appendix D).39,40 Specifically, the CBI-B assesses the following areas: 1) 
participant’s beliefs about maintaining independence and a positive attitude; 2) 
belief in their ability to participate in their medical care; 3) skills important for 
coping and stress management; and 4) capacity to manage their emotions in 
difficult situations.38 
Items are rated on a 9-point scale ranging from 1 (not at all confident) to 9 
(totally confident), and the self-efficacy score is calculated as the sum of all 12 
items.38 The CBI-B has been noted to have high internal consistency and 
concurrent validity among individuals with breast, prostate, colon, and lung 
cancer.39,40 Most individuals in our study took about 2 - 5 minutes to complete the 
CBI-B measure. 
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Malnutrition and Functional Status Assessment 
Malnutrition was assessed using the features of the Scored Patient-
Generated Subjective Global Assessment (PG-SGA),160 and based on their 
overall subjective ranking for nutritional and functional status, individuals were 
rated as being well nourished (SGA-A) or malnourished (SGA-B or SGA-C). 
Additionally, a total numerical PG-SGA score was also calculated; higher scores 
reflect poor nutritional status and a greater risk for malnutrition.161,184 
Hand grip strength was used to objectively assess changes in the 
functional status. Measurements were taken in both hands using a Grip-D 
dynamometer (Takei Scientific Instruments Co. Ltd., Japan). The dominant hand 
was tested first, and three successive measurements were taken for each 
hand.185 The time between the trials was about 15 seconds, and an average 
measurement for both hands was used for analysis. 
Statistical Analysis 
The data were analyzed using the SAS software, Version 9.4 (Copyright © 
2013 SAS Institute Inc., Cary, NC, USA). Descriptive statistics were used to 
calculate frequencies, means and standard deviation. One-way repeated 
measures ANOVA was performed to assess changes in mean EORTC QLQ-
C30, QLQ-H&N35, and self-efficacy scores over time. A post-hoc analysis with 
Bonferroni’s adjustment was done for multiple pairwise comparisons. 
Independent samples t-test assessed differences in mean EORTC QLQ-C30, 
QLQ-H&N35, and self-efficacy scores between malnourished and well-nourished 
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individuals. Guidelines from Osoba and colleagues186 were also used to 
determine whether the differences in the mean EORTC QLQ-C30 scores for 
malnourished and well-nourished individuals were clinically relevant. Accordingly, 
a difference of 5 -10 points represented little change, 10 - 20 points indicated a 
moderate change, and > 20 points indicated a large change in the 
difference.186,187 Multiple regression analysis was conducted to test the effect of 
PG-SGA rating, hand grip strength, and age as predictors on the global QoL 
score (dependent variable). Pearson’s correlation was used to examine the 
association between variables. Significance level was set at P ≤ 0.05. Figures 
were constructed using the GraphPad Prism version 6.07 for Windows, 
GraphPad Software, La Jolla California USA. 
Results 
Participants’ Clinical Psychological Diagnoses 
Thirty-two percent were clinically diagnosed with depression or depressive 
mood disorder, and another 32% with anxiety or anxiety disorder (Table 4-1). 
Adjustment disorder (21%), altered mental status (11%), insomnia (11%), and 
grief (5%) were other common psychological diagnoses among our participants. 
Table 4-1: Clinical psychological diagnoses among participants (n = 19).† 
 
 
 
 
 
 
 
 
 n % 
Depression (or Depressive mood disorder) 6 32 
Anxiety (or Anxiety disorder) 6 32 
Adjustment disorder 4 21 
Altered mental status 2 11 
Insomnia 2 11 
Grief 1 5 
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†Participants with multiple psychological diagnosis are included in this count. 
 
Longitudinal Changes in Quality of Life and Self-Efficacy Scores 
Physical functioning was significantly lower immediately before starting 
treatment (T1) compared to 1 month post-treatment (T2) (83 ± 26 vs. 86 ± 13, P 
= 0.007) (Table 4-2). Compared to T1, significantly greater problems with 
chewing, swallowing, sticky saliva, speech, and social eating, and losses in taste 
and smell sensations were reported at T2 (Table 4-3, Figure 4-1). When 
compared to T1, significantly more issues with dry mouth was reported at T2 (P = 
0.007) and T3 (P = 0.003) (Table 4-3). Although the mean self-efficacy score 
decreased from T1 to T2 (101 ± 20 vs 95 ± 27), this change was not significant. 
Quality of Life and Self-efficacy in Relation to Malnutrition and Functional 
Status Assessment 
Individuals who were categorized as malnourished per the PG-SGA had 
significantly lower global QoL score than those who were well-nourished (65 ± 15 
vs. 80 ± 19, P = 0.016) (Table 4-4). Cognitive functioning scores were 
significantly higher among well-nourished individuals than those who were 
malnourished (98 ± 6 vs. 83 ± 18, P = 0.038). The differences in the mean global 
QoL and cognitive functioning scores between malnourished and well-nourished 
participants was 15 points, indicating moderate clinical relevance. 
In the EORTC QLQ-C30, malnourished individuals scored significantly 
higher in the fatigue, pain, and appetite loss symptom scales/item than those 
who were well-nourished (P < 0.05) (Table 4-4, Figure 4-2). The differences in 
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the mean fatigue, pain, and appetite loss scores between the malnourished and 
well-nourished participants was > 20 points, indicating a larger clinical relevance. 
For the QLQ-H&N35, when compared to the well-nourished individuals, 
malnourished participants scored significantly higher in the swallowing, coughing, 
dry mouth, sticky saliva, and speech problem related scales and items (P ≤ 0.05) 
(Table 4-5, Figure 4-3). Malnourished participants had more troubles with 
chewing and social eating, felt more ill, and reported less enjoyment and/or 
interest in sex than those who were well-nourished (P < 0.05). The use of pain 
killers, feeding tube, and nutritional supplements was also reportedly higher 
among malnourished individuals (Table 4-5, Figure 4-3). 
The self-efficacy scores as measured by the CBI-B were not different 
between malnourished and well-nourished individuals (98 ± 21 vs. 105 ± 26, P = 
0.436). 
A significant correlation was noted between the global QoL and the PG-
SGA score (r = -0.37, P = 0.012) but not between the global QoL and the self-
efficacy scores (r = 0.25, P = 0.087). The correlation between the self-efficacy 
score and the PG-SGA score also did not reach significance (r= -0.21, P = 
0.171). The physical functioning score was correlated with the hand grip strength 
(r = 0.62, P < 0.0001) and with the five-times-sit-to-stand test (r = -0.56, P = 
0.0002). 
Multiple regression analysis indicated that the PG-SGA rating, hand grip 
strength, and age were significant predictors of the global QoL score (Table 4-6). 
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The overall model was also significant (F value = 20.47, P < 0.0001), and 60% of 
the variance in global QoL score could be predicted from the PG-SGA rating, 
hand grip strength, and age. 
Table 4-2: Changes in the EORTC QLQ-C30¥ and coping self-efficacy 
scores across time.* 
 Time 1 
(n = 19) 
Time 2 
(n = 15) 
Time 3 
(n = 13) 
P-value† 
Global Quality of Life 66 ± 17 69 ± 15 65 ± 16 0.725 
Functional Scales     
Physical functioning 83 ± 26 86 ± 13 83 ± 21 0.005a 
Role Functioning 66 ± 34 72 ± 26 65 ± 25 0.374 
Emotional functioning 79 ± 15 80 ± 12 75 ± 14 0.582 
Cognitive functioning 87 ± 16 86 ± 18 82 ± 20 0.133 
Social functioning 68 ± 20 73 ± 22 64 ± 21 0.477 
Symptom Scales/items     
Fatigue 35 ± 26 40 ± 13 38 ± 20 0.606 
Nausea and vomiting 6 ± 13 16 ± 25 14 ± 16 0.170 
Pain 32 ± 28 23 ± 24 21 ± 24 0.360 
Dyspnea 11 ± 22 13 ± 17 21 ± 26 0.067 
Insomnia 33 ± 22 29 ± 25 26 ± 20 0.494 
Appetite loss 33 ± 29 47 ± 28 46 ± 29 0.293 
Constipation 16 ± 23 20 ± 17 15 ± 17 0.312 
Diarrhea 7 ± 18 11 ± 16 10 ± 16 0.534 
Financial difficulties 28 ± 28 20 ± 17 21 ± 22 0.402 
Coping Self-efficacy 101 ± 20 95 ± 27 100 ± 15 0.746 
¥ Higher scores for global quality of life (QoL) and functional scales implies higher levels of global 
QOL or functioning; but higher scores in the symptom scales (or single items) indicate higher 
levels (or worsening) of symptoms. 
* Values are means ± standard deviation.  
†Analyzed by one-way repeated measures ANOVA. 
a Per the Bonferroni post-hoc test, pairwise comparison significant between Time 1 and Time 2 (P 
= 0.007 (adjusted)). 
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Table 4-3: Changes in the QLQ-H&N35 scores* across time. 
 
Time 1  
(n = 19) 
Time 2  
(n = 15) 
Time 3 
(n = 13) 
P-value† 
Pain 25 ± 19 31 ± 17 24 ± 25 0.434 
Swallowing problems 16 ± 18 27 ± 27 19 ± 18 0.023a 
Trouble smelling or tasting 27 ± 35 50 ± 28 42 ± 22 0.031a 
Speech problems 18 ± 23 29 ± 27 19 ± 25 0.010a 
Trouble eating socially 19 ± 23 36 ± 25 31 ± 28 0.031a 
Chewing problems¥ 30 ± 33 57 ± 27 52 ± 26 0.023a 
Trouble with social contact 9 ± 9 18 ± 22 14 ± 13 0.088 
Sex interest and/or enjoyment 22 ± 29 31 ± 33 28 ± 28 0.600 
Teeth problems 14 ± 28 5 ± 13 13 ± 29 0.303 
Trouble opening mouth wide 21 ± 34 22 ± 27 13 ± 17 0.775 
Dry mouth 18 ± 23 47 ± 21 49 ± 22 0.003a,b 
Sticky saliva 21 ± 34 58 ± 29 38 ± 23 0.002a 
Coughing 30 ± 19 40 ± 29 33 ± 27 0.652 
Felt ill 14 ± 20 22 ± 21 23 ± 25 0.374 
Pain killers 74 ± 45 80 ± 41 62 ± 51 0.695 
Nutritional supplements 42 ± 51 73 ± 46 69 ± 48 0.108 
Feeding tube 37 ± 50 73 ± 46 38 ± 51 0.063 
Weight loss 58 ± 51 33 ± 49 46 ± 52 0.285 
Weight gain 0 20 ± 41 23 ± 44 0.070 
* Values are means ± standard deviation. 
¥ Scale assessing problems with chewing is not included in the QLQ-H&N35. 
†Analyzed by one-way repeated measures ANOVA. 
a,b Per the Bonferroni post-hoc test, pairwise comparisons (adjusted P values): 
a P < 0.05 between T1 and T2. 
b P = 0.003 between T1 and T3. 
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Figure 4-1: Longitudinal changes in the physical functioning and disease- 
and treatment-related symptoms. 
 
 
 
* Pairwise comparison significant between Time 1 and Time 2 
¥ Pairwise comparison significant between Time 1 and Time 3
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Table 4-4: EORTC QLQ-C30¥ and coping self-efficacy scores* for 
individuals categorized as malnourished (PG-SGA B or C) versus well-
nourished (PG-SGA A). 
 
¥ Higher scores for global quality of life (QoL) and functional scales implies higher levels of 
global QOL or functioning; but higher scores in the symptom scales (or single items) indicate 
higher levels (or worsening) of symptoms. 
*Values are means ± standard deviation. 
†Analyzed by independent samples t-test. 
 
 
 
 
 
 
 
 
 
 
Malnourished 
(n = 40) 
Well-nourished 
(n = 7) 
P-value† 
Global Quality of Life 65 ± 15 80 ± 19 0.016 
Functional Scales    
Physical functioning 83 ± 20 87 ± 27 0.688 
Role Functioning 66 ± 29 79 ± 28 0.281 
Emotional functioning 77 ± 13 83 ± 19 0.288 
Cognitive functioning 83 ± 18 98 ± 6 0.038 
Social functioning 67 ± 21 76 ± 19 0.286 
Symptom Scales/items    
Fatigue 41 ± 19 19 ± 21 0.008 
Nausea and vomiting 13 ± 19 0 0.077 
Pain 29 ± 26 7 ± 13 0.035 
Dyspnea 14 ± 21 14 ± 26 0.989 
Insomnia 31 ± 22 24 ± 25 0.447 
Appetite loss 47 ± 27  10 ± 16 0.001 
Constipation 18 ± 20 14 ± 18 0.692 
Diarrhea 11 ± 18 0 0.112 
Financial difficulties 25 ± 24 14 ± 18 0.259 
Coping Self-efficacy 98 ± 21 105 ± 26 0.436 
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Figure 4-2: A comparison between the mean EORTC QLQ-C30 scores between well-
nourished and malnourished individuals. 
 
 
Figure 4-3: A comparison between the mean QLQ-H&N35 scores* between well- nourished 
and malnourished individuals. 
 
*Scale assessing problems with chewing is not included in the QLQ-H&N35. 
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Table 4-5: EORTC QLQ-H&N35 scores* for individuals categorized as 
malnourished (PG-SGA B or C) versus well-nourished (PG-SGA A). 
 
Malnourished 
(n=40) 
Well-nourished 
(n=7) 
P-value† 
Pain 28 ± 21 18 ± 12 0.221 
Swallowing 23 ± 22 2 ± 4 0.017 
Senses problems 40 ± 29 31 ± 41 0.481 
Speech problems 25 ± 26 5 ± 9 0.048 
Trouble with social eating 32 ± 26 5 ± 8 0.008 
Chewing problems¥ 51 ± 28 11 ± 21 0.001 
Trouble with social contact 15 ± 16 6 ± 6 0.168 
Sex interest and/or enjoyment 30 ± 27 7 ± 13 0.036 
Teeth problems 12 ± 26 5 ± 8 0.464 
Trouble opening mouth wide 18 ± 26 24 ± 37 0.633 
Dry mouth 40 ± 25 10 ± 16 0.004 
Sticky saliva 44 ± 29 0 0.0002 
Coughing 38 ± 24 14 ± 18 0.019 
Felt ill 23 ± 22 0 0.001 
Pain killers 80 ± 41 29 ± 49 0.004 
Nutritional supplements 68 ± 47 14 ± 38 0.007 
Feeding tube 55 ± 50 14 ± 38 0.048 
Weight loss 53 ± 51 14 ± 38 0.064 
Weight gain 13 ± 34 14 ± 38 0.899 
*Values are means ± standard deviation. 
†Analyzed by independent samples t-test. 
¥Scale assessing problems with chewing is not included in the QLQ-H&N35. 
 
 
Table 4-6: Significant predictors for global quality of life (or global function) 
as identified by the multiple regression analysis. 
 
Beta-coefficients* 
95% Confidence 
Intervals 
P-value 
Global Quality of Life    
PG-SGA rating† -0.44 -29.98 -9.54 0.0003 
Hand grip strength 0.39 0.41 1.51 0.001 
Age -0.45 -1.66 -0.53 0.0003 
* Standardized regression coefficients 
†1 = Malnourished (PG-SGA B or C), 0 = Well-nourished (PG-SGA A). 
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Discussion 
This study is novel because it investigated longitudinal quality of life (QoL) 
and self-efficacy perceptions in the context of malnutrition among individuals with 
advanced head and neck cancers in an outpatient setting. We found that 
participants who were categorized as malnourished by the PG-SGA scored 
significantly lower in the global QoL and cognitive functioning scales than those 
who were well-nourished, and the mean difference was 15 points, which also 
suggests clinical relevance based on the guidelines provided by Osoba and 
colleagues.186 Limited research has been conducted using the PG-SGA as a 
diagnostic criteria for malnutrition and investigating its relationship to QoL 
symptoms in the HNC setting. In a heterogeneous sample of ambulatory patients 
receiving radiation to the head, neck, abdominal, or rectal area, Isenring et al184 
found a significant correlation between the PG-SGA score and the EORTC global 
QoL score at baseline and 4 weeks after treatment (P < 0.001). Likewise, we 
reported a significant association between the global Qol score and the PG-SGA 
score, suggesting a relationship between an impaired QoL and malnutrition. 
We also found that malnourished participants scored significantly higher in 
the disease- and treatment-related symptom scales and items compared to those 
who were well-nourished. Specific symptoms that impact oral intake such as dry 
mouth, sticky saliva, coughing, and problems with chewing and swallowing had 
significantly higher scores for malnourished individuals. A > 20 point difference in 
the mean appetite loss, pain, and fatigue symptom scales/item was noted 
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between the malnourished and well-nourished participants; this difference was 
not only statistically significant but also of higher clinical relevance as per the 
Osoba et al186 guidelines. 
Other QoL symptoms such as trouble with social eating, feeling more ill, 
speech problems, and sexual issues were reportedly higher among malnourished 
participants. Previous research among individuals with HNC has yielded mixed 
findings while comparing the EORTC scales in relation to malnutrition. In one 
cross-sectional analysis in Sweden, when compared with the well-nourished 
participants, those who were malnourished [identified by the weight index (WI) < 
0.80, WI= (actual weight/reference weight)] scored poorly in the global QoL and 
physical and role functioning scales, but these differences were not statistically 
significant.188 In the Netherlands, Jager-Wittenaar and colleagues33 reported that 
malnourished oral and oropharyngeal cancer participants [identified by ≥ 10% 
weight loss in 6 months or ≥ 5% loss in 1 month] scored significantly lower in the 
EORTC physical functioning and fatigue scales when compared with the well-
nourished participants, but no other EORTC scale yielded significant differences 
between the two groups. In a retrospective observation involving individuals with 
colorectal cancer in the US, malnourished individuals [identified by the subjective 
global assessment (SGA)189] scored worse in the EORTC symptom and 
functional scales than those who were well-nourished.187 One reason for such 
mixed findings while comparing malnourished and well-nourished individuals 
could be that the choice of nutrition assessment method used for the 
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identification of malnutrition could possibly yield differences in the EORTC 
scales’ results. 
To our knowledge, research investigating QoL outcomes as identified by 
the PG-SGA assessment tool has not been conducted exclusively among 
individuals with head and neck cancers. However, reports among individuals with 
gastric cancers190 have shown that PG-SGA-identified malnourished individuals 
score significantly higher in the EORTC symptom scales and lower in the 
functional scales when compared with the PG-SGA categorized well-nourished 
individuals. Our study confirms these findings in the advanced HNC patient 
population, although additional research is certainly needed for additional 
insights on how QoL outcomes relate to malnutrition. 
Longitudinal Changes in the Quality of Life 
Interestingly, our participants reported lower physical functioning before 
treatment initiation than one month after treatment. One reason for low physical 
function before treatment could be that 68% of our participants had undergone 
surgical resection immediately before treatment and therefore were not physically 
active during this period. We found that compared to pre-treatment symptoms, 
individuals scored significantly higher with regards to problems with chewing, 
swallowing, sticky saliva, sense of taste and smell, speech, and social eating one 
month after the completion of treatment. Furthermore, dry mouth was reported as 
a significant problem even 3 months after the completion of treatment. An 
observation in Sweden177 reported that while significant deterioration in the HNC 
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treatment and disease-related symptoms was observed 3 months after the 
treatment completion, problems with teeth, sense of taste and smell, and dry 
mouth persisted even 3 years after the diagnosis. These results suggest that the 
treatment and disease induced symptoms that negatively affect an individual’s 
quality of life could possibly last years after the completion of treatment, and 
therefore may require routine follow-up through clinical assessment. 
Quality of Life and Functional Status Outcomes 
Our results indicated that individuals with higher EORTC physical 
functioning score had better hand grip strength and took less time to complete 
the five-times-sit-to-stand test, indicating a strong association between the 
subjective and objective markers of functional status. It has also been suggested 
that changes in muscle strength affect functional status and quality of life 
outcomes.18 In one observation involving participants with gastric cancers, those 
categorized as malnourished per the reduced hand grip strength values [grip 
strength below 85% of the age and sex-adjusted reference] had significantly 
lower EORTC global QoL scores than well-nourished participants.190 In our 
study, besides age, hand grip strength and malnutrition identified by the PG-SGA 
tool were significant predictors of global QoL score, suggesting that impaired 
functional status and malnutrition are associated with poor quality of life 
outcomes. Similar findings have been reported in a mixed sample of individuals 
with gastrointestinal, head and neck, urinary tract, and gynecologic cancers, 
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where malnutrition identified by the SGA189 emerged as an independent 
determinant for EORTC physical function status.21  
Self-Efficacy and Its Relation with Malnutrition 
In regards to the CBI-B measure, no significant changes in the coping self-
efficacy scores were noted over the course of this study. Because statistical 
significance was not reached, we cannot say for certain that malnourished 
individuals experienced lower coping self-efficacy compared to those who were 
well-nourished. Similarly, neither the association between the self-efficacy score 
and the PG-SGA score (r = -0.21) nor the self-efficacy score and global QoL 
score (r = 0.25) reached statistical significance; however, it is interesting to note 
that they were in the anticipated direction. This suggests that individuals who 
experienced lower coping self-efficacy could have had poor nutritional status and 
reported impaired QoL but additional research is warranted to further explore 
these relationships. 
In the past, psychosocial oncology research has not investigated the 
relationship between self-efficacy and nutritional outcomes. In another area, 
studies involving heterogeneous cancer sites including HNC have reported that 
depression is a potential risk factor for lower self-efficacy.36 Although we did not 
assess depression in the current study, one-third of our sample was clinically 
diagnosed with depression or depressive mood disorders; future research could 
investigate whether depression relates to coping self-efficacy among individuals 
with HNC. Another investigation found that pre-treatment patient education 
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regarding upcoming treatment-related expectations, side-effects, and social 
support may reduce anxiety and increase self-efficacy among individuals 
receiving radiation therapy.191 Therefore, while some investigators suggest that 
oncology patients with higher self-efficacy experience less anxiety and 
depressive symptoms and cope better with their disease and prognosis,36,38,39 as 
we found, the relation between self-efficacy perceptions and other health 
outcomes including nutritional status still remains unclear and needs additional 
investigation. 
Conclusion and Future Directions 
So far, very limited research has been conducted in the US that has 
explored the association between malnutrition and QoL outcomes among the 
vulnerable HNC population. Our results suggest that individuals with advanced 
HNC who were identified as malnourished using the PG-SGA tool have poor 
quality of life symptoms compared to those who were categorized as well-
nourished. Specifically, malnourished participants scored significantly lower in 
the global QoL and cognitive function scales and significantly higher in the 
disease- and treatment-related symptom scales and items. Malnutrition and 
impaired functional status as measured by the hand grip strength were significant 
predictors of global QoL. No significant differences in the self-efficacy scores 
were noted over time or between malnourished and well-nourished individuals, 
although additional research is certainly needed to explore how self-efficacy 
attitudes relate to nutritional outcomes. 
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Our results also indicate a need for regular nutritional and psychosocial 
assessments during various phases of the HNC treatment. About 60% of our 
participants were diagnosed with depression, anxiety, or related disorders, and 
malnourished individuals experienced fatigue, speech issues, difficulties with 
social eating, and also reported impaired cognitive function. Therefore, early 
detection of malnutrition could help with patient-specific intervention strategies 
aimed to improve disease- and treatment-related symptoms and health-related 
QoL. It has also been found that many HNC survivors feel hesitant to discuss 
their psychosocial well-being with their physicians.192 Therefore, future clinicians 
would need to be proactive in assessing individuals’ nutritional and psychosocial 
status through cancer-specific tools such as the PG-SGA and the EORTC 
questionnaires. Regular assessment would also help with the identification of 
individuals who may benefit from psychosocial support and rehabilitative services 
that an oncology treatment center has to offer. 
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CHAPTER 5: OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
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In conclusion, the results from this dissertation research indicate that 
individuals with HNC are malnourished even before treatment initiation. Using the 
Consensus criteria, 67% of our participants were malnourished before treatment; 
and the prevalence of malnutrition consistently increased during treatment and 
the post-treatment period. When compared to our chosen reference standard 
PG-SGA, the Consensus criteria identified malnutrition in individuals with HNC 
with overall good sensitivity (95%) and specificity (43%). Additionally, it was 
found that the BIA parameters PA and IR might be useful in identifying 
individuals who are at increased risk for malnutrition and/or impaired functional 
status. However, given that this was a small homogenous sample of HNC, 
additional research is certainly warranted to investigate the broader clinical utility 
of BIA in detecting malnutrition using the new Consensus framework in other 
clinical populations. Research is also needed to validate the Consensus 
malnutrition diagnostic framework in hospital and ambulatory care settings. 
From a psychosocial perspective, we found that compared with well-
nourished participants, malnourished individuals scored significantly lower in the 
global QoL and cognitive function scales and significantly higher in the disease- 
and treatment-related symptom scales and items. No significant differences in 
the self-efficacy scores were noted over time or between malnourished and well-
nourished individuals, although additional research is certainly needed for 
insights on how self-efficacy and quality of life relates to nutritional outcomes. 
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Taken together, these results suggest a need for regular nutritional and 
psychosocial assessments during various phases of HNC treatment. In the 
future, training dietitians to identify the malnutrition diagnostic characteristics and 
working collaboratively with the physician team for standardization of malnutrition 
coding practices in medical records are some of the important steps for timely 
diagnosis of malnutrition. Importantly, if clinicians are trained to assess 
malnutrition diagnostic markers before individuals with cancer undergo 
aggressive treatments, nutritional interventions could be initiated at an earlier 
time and loss in weight and/or lean tissue can be prevented. That said, research 
is also needed on how early nutrition interventions impact malnutrition in head 
and neck cancer.  
Early detection of malnutrition could also help with the implementation of 
patient-specific intervention strategies aimed to improve overall health-related 
QoL. Similarly, timely psychosocial screening can help identify individuals who 
would benefit from rehabilitative programs and similar support services that are 
offered at an oncology treatment center. Therefore, future research should focus 
with the aim of providing evidence-based care in the oncology population and 
incorporate comprehensive nutritional and psychosocial outcome measures at 
various time-points during the course of treatment.  
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Appendix A: Consent Form 
University of Minnesota, Twin Cities 
Department of Food Science and Nutrition 
 
Study Title:  Nutritional Status among Individuals with Head and Neck Cancer. 
 
You are invited to participate in a research study that will assess your nutritional status 
and well-being. You were selected as a possible participant because you have been 
diagnosed with head and neck cancer, and will be undergoing chemotherapy and 
radiation therapy. We ask that you read this form and ask any questions that you may 
have before agreeing to participate in the study. 
 
This study is being conducted by Associate Professor Carrie P. Earthman, PhD, RD, LD 
and Graduate Research Assistant Urvashi Mulasi, MS, RD of the Department of Food 
Science and Nutrition, in collaboration with Naomi Fujioka, MD; Gautam Jha, MD; 
Manish Patel, DO; and Venkatesh Rudrapatna, MD, MPH; head and neck physicians at 
the Masonic Cancer Clinic and Radiation Oncology Clinic at the University of Minnesota 
Medical Center, Fairview. 
 
STUDY PURPOSE 
The purpose of this study is to examine your nutritional status, including body weight and 
composition (i.e., muscle and fat), and dietary intake, during and up to 3 months after 
your treatment. We are also interested in knowing how your diagnosis of cancer and 
treatment might affect your well-being and the way you feel about your social 
interactions. 
 
GENERAL OVERVIEW 
Once you have provided your informed consent to participate in the study, the study staff 
will orient you with the general information regarding the study procedures. 
 
We anticipate to enroll about 40 individuals with head and neck cancer. We will collect 
data during the following five times in your treatment: 1) Within 7 days prior to starting 
the treatment; 2)About 3.5 weeks (± 1 week) into treatment; 3) During the last week of 
your treatment; 4) One month (± 14 days) after you complete your treatment; and 5) 
Three months (± 1 month) after treatment. For the first three times, data will be collected 
during your routine chemotherapy appointments. For the remaining two times (after 
treatment is completed), you may be asked to go to the Delaware Clinical Research Unit 
instead of going to the Masonic Cancer Clinic. 
 
During each visit, it might take up to 2 hours of your time in order for us to collect 
measurements and for you to answer study questions. If you wish so, you can take a 
break from the study and participate when you feel you are ready. Let the study staff 
know if you feel you need a break from study procedures. 
 
Your decision to participate in this study is not necessary for your treatment. Your 
participation will not affect your standard treatment and care in any manner.  
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STUDY PROCEDURES 
 
Medical History 
During the course of the study, your medical records will be reviewed and you may be 
asked questions so that we can learn about your medical and health history. Your 
medical records will also be reviewed for your demographic information including age, 
education level, ethnicity/race, income, occupation, and number of people in your 
household.   
 
Anthropometry (body measurements) and Nutritional Assessment 
You will be asked to remove your outer clothing, so that you are dressed only in 
underwear, socks, and a hospital gown during measurements. Your height and body 
weight will be measured at your first visit, and your body weight will be measured again 
at each subsequent visit.  Height will be measured using a standard stadiometer and 
body weight will be measured with a stand-on scale. Using a skinfold caliper, we will 
measure your upper arm skinfold thickness (called triceps skinfold), and your overall arm 
circumference will also be recorded using a measuring tape (called mid-upper-arm 
circumference). 
 
At each of the five study time points, a trained staff will perform a nutritional assessment 
on you, where you will be asked questions about changes in your body weight, dietary 
intake, appetite, and if you have nausea, vomiting, diarrhea, or constipation. In addition, 
a brief physical examination will be conducted by the study staff in order to assess any 
changes in muscle and fat tissue in your arms, shoulders, and legs. 
 
Body Composition by Bioimpedance Spectroscopy 
Your muscle and fat tissue, and water in the body will be measured by bioelectrical 
impedance at each of the five times.  Four sticky electrodes will be placed on your right 
hand and foot after cleaning with alcohol, and then a small bioelectrical current that you 
will not be able to feel will be sent through wires attached to the electrodes. Several 
measurements will be made up to 30 minutes after you lie down. 
 
Dietary Intake 
At each of the five times, you will be asked what you ate and drank on the previous day; 
this is called a 24-hour dietary recall. During the dietary recall interview, we will ask you 
additional questions to estimate the portion sizes, and to know more about the types, 
brands, and cooking methods of the items consumed.  
 
In the beginning of the study, you will be taught how to measure what you eat and drink. 
The study staff will also educate you on keeping 3-day food records, which will involve 
writing down everything that you eat and drink, including dietary supplements, in a food 
record on 3 assigned days during the week before your next scheduled treatment.  One 
of those 3 days will be the day before your treatment, and you will bring your food record 
with you on the day of your appointment. The study staff will review your 3-day food 
records with you and we may ask you additional questions about what you ate and 
drank. During the week before your next scheduled appointment, the study staff will call 
to remind you to record your dietary intake and to bring the food record with you at your 
next appointment. 
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Functional Status 
At each of the five study time points, your muscle strength will be measured using a 
hand grip dynamometer. Your physical function will also be checked using the five-
times-sit-to-stand-test, where you will be asked to rise and sit from an armless chair five 
times in a row. 
 
Quality of Life and Self-efficacy  
You will be asked some questions about your health, symptoms or problems, emotions, 
sexual life, and social functioning once before you start your treatment, and twice after 
the completion of treatment. 
 
The ‘Quality of life’ questionnaire will have general questions about your health, 
symptoms, mood and emotions, and social life. A specific subset of questions will ask 
whether you experience any pain, weakness, nausea, vomiting, diarrhea, constipation, 
lack of appetite, or difficulties with chewing and swallowing. The ‘Self-efficacy’ (i.e. 
coping with cancer) questionnaire will ask you about your confidence in maintaining an 
independent and positive attitude, and emotional management during stressful 
situations. 
 
RISKS OF STUDY PARTICIPATION 
This study has minimal risks, which are described as follows. 
 
You may feel that some of the questions that you are asked about your cancer related 
symptoms, personal history, emotions, and social life may be stressful or upsetting to 
answer. You will be asked questions regarding your personal health habits, 
gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation), appetite, and food 
intake. You will also be asked questions on how you cope with cancer and beliefs about 
your personal life satisfaction including sexual activity. Being asked such questions may 
be considered possible invasion of privacy. If you do not wish to answer a question, you 
may skip it and go to the next question, or you may stop immediately. If you become 
upset, please let the study staff know.  
 
Another risk may be loss of confidentiality. Your health record for the study may be 
reviewed by departments at the University, with appropriate regulatory oversight. Study 
data will be encrypted according to the current University policy for protection of 
confidentiality. Every effort will be made to keep your study records confidential but we 
cannot guarantee it.  
 
Specifically, your medical records will be reviewed for information, including your 
diagnosis, current and past medical history, laboratory data,  medications, smoking and 
exercise history, alcohol consumption, type of treatment, response to treatment, and 
ongoing medical notes. Your medical records will also be reviewed for your demographic 
information including age, education level, ethnicity/race, income, occupation, and 
number of people in your household. Review of such information may be considered 
possible invasion of privacy. 
 
BENEFITS OF STUDY PARTICIPATION 
There are no benefits to you for participating in this study.  This study may not help you, 
but we hope that the information from this study will help increase awareness among 
 146 
 
researchers about how nutritional status impacts care outcomes among individuals with 
head and neck cancer. We also hope that the results from this study will help improve 
nutritional management and care strategies for individuals with head and neck cancer. 
 
STUDY COSTS AND PARTICIPANT COMPENSATION 
You will not be charged for any of the procedures or materials used in this study.  We do 
not have any compensation for your inconvenience and time spent participating in this 
study. 
 
RESEARCH RELATED INJURY 
In the event that this research activity results in an injury, treatment will be available, 
including first aid, emergency treatment, and follow-up care as needed. Care for such 
injuries will be billed in the ordinary manner to you or your insurance company. If you 
think that you have suffered a research related injury, let the study staff know right away. 
 
CONFIDENTIALITY 
The records of this study will be kept private. All records will be coded and kept in a 
locked file.  In any publications or presentations, we will not include any information that 
will make it possible to identify you as a subject. Your record for the study may, however, 
be reviewed by departments at the University, with appropriate regulatory oversight.  If 
you have not been seen before at the University of Minnesota Medical Center, Fairview, 
a permanent medical record will be created at the hospital under your name. Your study 
data will be added to your medical record.  While confidentiality cannot be guaranteed, it 
will be protected to the fullest extent possible. Study data will be encrypted according to 
the current University policy for protection of confidentiality.  
 
PROTECTED HEALTH INFORMATION (PHI) 
Your PHI created or received for the purposes of this study is protected under the 
federal regulation known as HIPAA.  Refer to the attached HIPAA authorization for 
details concerning the use of this information.  
 
VOLUNTARY NATURE OF THE STUDY 
Participation in this study is voluntary. Your decision whether or not to participate in this 
study will not affect your current or future relations with the University of Minnesota, 
Masonic Cancer Clinic, or the Radiation Oncology Clinic.  If you decide to participate, 
you are free to withdraw at any time without affecting these relationships. Refusal to 
participate will involve no penalty or decrease in any benefits to which you may be 
otherwise entitled. 
 
CONTACT INFORMATION AND QUESTIONS 
The researchers conducting this study are Associate Professor Carrie P. Earthman, 
PhD, RD, LD and Graduate Research Assistant Urvashi Mulasi, MS, RD of the 
Department of Food Science and Nutrition, in collaboration with Naomi Fujioka, MD; 
Gautam Jha, MD; Manish Patel, DO; and Venkatesh Rudrapatna, MD, MPH; head and 
neck physicians at the Masonic Cancer Clinic and Radiation Oncology Clinic at the 
University of Minnesota Medical Center, Fairview. 
 
You may ask any questions you have now, or if you have questions later, you are 
encouraged to contact Dr. Earthman at 612-624-9278.  If you have any questions or 
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concerns regarding the study and would like to talk to someone other than the 
researcher(s), you are encouraged to contact the Fairview Research Helpline at 
telephone number 612-672-7692 or toll free at 866-508-6961.  You may also contact this 
office in writing or in person at Fairview Research Administration, 2433 Energy Park 
Drive, St. Paul, MN  55108. 
 
You will be given a copy of this form to keep for your records. 
 
STATEMENT OF CONSENT 
I have read the information provided in this consent form.  All of my questions have been 
answered to my satisfaction. The study’s purpose, procedures, and possible risks and 
benefits have been explained to me. I have been told that my participation is voluntary 
and if I wish so, I am free to withdraw any time.  
 
By signing below, I consent to participate in the study. 
 
 
Signature of Subject__________________________________________________   
 
Date_________________ 
 
 
Signature of Person Obtaining Consent___________________________________ 
 
Date_________________ 
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University of Minnesota, Twin Cities 
Department of Food Science and Nutrition 
Nutritional Status among Individuals with Head and Neck Cancer:  
Demographic, Medical, and Anthropometric Data Visit 1 
Participant initial and ID :____________ Visit Date  (mm/dd/yyyy): _____________ 
 
Measurement time-point (Circle): T1      T2      T3      T4      T5 
 
Researcher Initial ______________________________________ 
                                       
Part I. DEMOGRAPHIC INFORMATION 
Age :______________  
Gender:  Male ☐             Female ☐ 
Part II. MEDICAL DIAGNOSIS 
Tumor localization: 
Oral Cavity ☐          
Oropharynx ☐               
Hypopharynx ☐ 
Maxillary Sinuses ☐ 
Larynx  ☐ (Specify Site:  Supraglottis ☐       Glottis ☐         Subglottis ☐) 
Other:  _______________ 
 
 
TNM Staging:    ____________________   
 
Stage 0 ☐  Stage I ☐    Stage II ☐    Stage III ☐     Stage IVA ☐    Stage IVB ☐   Stage IVC  
☐      Other (specify) _________ 
         
Part III. ANTHROPOMETRIC DATA 
 
Height (cm)  ________________           
 
Current Weight (0.1 kg) _______________ 
Weight 1 month ago: 
_________
  
Weight 3 months ago:__________ 
Weight 6 months ago:__________ 
Percent weight loss from current weight (identify the time frame):______________ 
If malnourished based on weight history, identify whether Nonsevere (moderate) or 
Severe____________ 
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Triceps skinfold thickness (0.1mm)   (1)______________ (2)______________ 
(3)____________ 
 
 
Mid-upper-arm circumference (0.1cm) (1)______________ (2)______________ 
 
Hand Grip Strength: Dominant hand (R/L): ___________                        
 
Right (#1):  ________________kg     
Right (#2):  ________________kg          
Right (#3):  ________________kg              
 
Mean value of the three trials (R):  _____________kg 
 
Left (#1):  ________________kg 
Left (#2):  ________________kg   
Left (#3):  ________________kg   
 
Mean value of the three trials (L):  _____________kg 
 
 
Five-times-sit-to-stand-test: 
Time after landing the fifth stand up __________ seconds 
 
 
Other notes/observation: 
 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________ 
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University of Minnesota, Twin Cities 
Department of Food Science and Nutrition 
Nutritional Status among Individuals with Head and Neck Cancer 
Demographic, Medical, and Anthropometric Data Visits 2 - 5 
Participant initial and ID # :____________ Visit Date  (mm/dd/yyyy): _____________ 
 
Measurement time-point (Circle):    T2      T3      T4      T5 
 
Researcher Initial ______________________________________ 
                                                                        
ANTHROPOMETRIC DATA 
 
Current Weight (0.1 kg) _______________ 
Weight 1 month ago: _________ 
Weight 3 months ago:__________ 
Weight 6 months ago:__________ 
Percent weight loss from current weight (identify the time frame):______________ 
If malnourished based on weight history, identify whether Nonsevere (moderate) or Severe 
____________ 
__________________________________________________________________________
________________ 
Triceps skinfold thickness (0.1mm)   (1)______________ (2)______________ 
(3)____________ 
 
 
Mid-upper-arm circumference (0.1cm) (1)______________ (2)______________ 
Hand Grip Strength: Dominant hand (R/L): ___________                        
 
Right (#1):  ________________kg     
Right (#2):  ________________kg          
Right (#3):  ________________kg          
     
Mean value of the three trials (R):  _____________kg 
 
Left (#1):  ________________kg 
Left (#2):  ________________kg   
Left (#3):  ________________kg   
 
Mean value of the three trials (L):  _____________kg 
Five-times-sit-to-stand-test:  
Time after landing the fifth stand up __________ seconds  
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Hand Grip Strength  
Participant Initials and ID #::  _______________ Date:  _____________________ 
 
Dominant hand (R/L): ___________                         
 
Measurement (Circle):  T1      T2      T3      T4      T5  
  
Instructions:  
Don’t press the On/C button while the inner grip is being gripped.  Release pressure 
from the grip as soon as the measurement is over.  The device starts measurement 
when a force of 5 kg is reached and judges the measurement is over when the force 
decreases below 4 kg. 
 
Hold the device so that the grip meter indicator faces outward.  Turn the knob to adjust 
the grip width so that the second joint of the pointing finger makes a right angle. 
 
1. Press the On/C button. 
2. Measurement position: Sit comfortably with shoulder adducted and forearm 
neutrally rotated, elbow flexed to 90°. The forearm and wrist should be in neutral 
position. 
3. Test the dominant hand first. 
4. Verbal instructions: "I want you to hold the handle like this and squeeze as hard as 
you can." The examiner demonstrates and then gives the dynamometer to the 
subject. After the subject is positioned appropriately, the examiner says, "Are you 
ready? Squeeze as hard as you can." (The dynamometer was lightly held around the 
readout dial by the examiner to prevent inadvertant dropping). As the subject begins 
to squeeze. say, "Harder! ... Harder! ... Relax." 
5. Take three successive measurements for one hand and then the other hand. (The 
time between trials was should be about 15 seconds, which is the time needed to 
read and record each score). The mean of the three trials will be used for data 
analysis. 
6. Turn the instrument off when all measurements are completed. 
 
Right (#1):  ________________kg     
Right (#2):  ________________kg          
Right (#3):  ________________kg              
 
Left (#1):  ________________kg 
Left (#2):  ________________kg   
Left (#3):  ________________kg   
 
Mean value of the three trials (R):  _____________kg 
Mean value of the three trials (L):  _____________kg 
 
Researcher Initials and Signature _____________________________________ 
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Five-times-sit-to-stand-test 
 
Subject Initials and ID #:  ______________ Date:  _____________________ 
 
Measurement time-point (Circle):  T1      T2      T3      T4      T5 
 
Measurement instructions: 
 
1. Use a slightly padded armless chair with a standard seat height between 40-45 cm. 
2. Stabilize the chair, preferably against a wall. 
3. Have the patient come forward and sit on the chair seat until their feet are flat on the 
floor and the back is upright against the back rest of the chair. 
4. Have the patient fold the upper limbs across the chest and sit with the back against 
the upright back rest of the chair. 
5. Instruct the patient to stand up all the way and sit down once without using the upper 
limbs. 
6. If the patient is able to complete the maneuver without the upper limbs or physical 
assistance, instruct him or her to stand up all the way and sit down landing firmly, as fast 
as possible, 5 times without using the arms. Guard the patient as necessary. 
7. Using a watch, begin timing on the command “go” and cease timing on landing after 
the fifth stand up. (i.e., record the time from the command “go” (the patient is sitting) until 
the patient’s back touches the backrest of the chair on the fifth repetition) 
8. Abort the test and start all over again if the patient fails to stand up all the way or sit 
down firmly. 
 
 
Time after landing the fifth stand up __________ seconds 
 
 
 
Researcher Initials ________________________________________ 
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Body Composition  
 
Subject Initials and ID #:  ________________ Date:  _____________________ 
 
Measurement time-point (Circle):  T1      T2      T3      T4      T5  
 
WEIGHT without shoes (kg) __________ 
  
HEIGHT without shoes (cm) __________ 
 
AGE (years)  _____________ 
 
Record everything that the subject has consumed that morning, including food and 
beverages, water provided with meds, IV meds, etc. leading up to the measurement. 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________ 
 
Have subject void bladder just before you ask them to lie down. 
 
1. Electrode Placement: 
 
a. If possible, the electrodes should be placed on the right side of the body, but 
they may have to be placed on the left side due to logistical considerations. Please 
indicate on which side of the body the electrodes have been placed: 
 
 LEFT  RIGHT 
 
Indicate the circumstances that mandate that the electrodes be placed on the left 
side:______________________________________________________________ 
_____________________________________________________________________ 
(Note: All subsequent measurements should be made on the SAME SIDE of the body as 
was used for the first measurement) 
 
 
b. Distance measured between the electrodes on hand: _______________ 
(Please measure the distance from the top of the wrist electrode to the top of the 
metacarpal electrode) 
 
Distance measured between the electrodes on foot:  ________________ 
(Please measure the distance from the top of the ankle electrode to the top of the 
metatarsal electrode) 
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2. Measurements: 
 
a. TIME laid in supine position:____________ 
 
Is the patient lying flat?   YES       NO 
If supine position is not possible, indicate the position when measurement is being 
taken_______________________ 
(Note: If supine position is not possible, head of bed should be elevated to 30 
degrees or less) 
 
If NO, please describe the HOB elevation and/or other details on body position:   
______________________________________________________________________
______________________________________________________________________ 
 
b. Measurements: 
 
QuadScan Device (Black lead wire is 
attached to electrode closest to the heart) 
MultiScan Device (Black lead wire is 
attached to electrode closest to the 
heart) 
 
4-MIN (Test #____________): 
 
 
 
5-MINUTE  (Test #____________):  
 
 
 
 
9-MIN (Test #__________): 
  
 
 
10-MINUTE (Test #____________): 
 
 
  
 
Researcher Initials:  
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24-Hour Dietary Recall 
Visit (Circle): T1      T2      T3      T4      T5 
 
Date: __________________________ Daily Physical Activity Involvement:________________________________ 
 
Age: ___________________             Height:  ____________        Weight: _________________ 
 
TIME 
Foods/Beverages/Supplements Consumed 
(Include method of preparation, brand names, condiments added,  & 
other details) Serving Size LOCATION 
 
 
 
    
 
 
 
 
 
     
 
 
 
 
 
    
 
 
 
    
  
        Name ______________________ 
 157 
 
TIME 
Foods/Beverages/Supplements Consumed 
(Include method of preparation, brand names, condiments added,  & 
other details) Serving Size LOCATION 
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University of Minnesota 
Department of Food Science and Nutrition 
Nutrition Study 
 
Food Intake Record Booklet 
 
Number of days to Record:  3 days before your next scheduled chemotherapy appointment.  
Bring this booklet with you on your next chemotherapy appointment. 
 
 
Name:        Participant ID:   
 
 
Recording Day/Days: 
 
 
 
 
 
 
 
Bring with you for next visit on: 
 
 
Questions?  Call Study Coordinator Urvashi Mulasi at 952-303-2046 
 
Packet developed using materials from the University of Arizona Nutritional Assessment Laboratory, Dept. of Nutritional Sciences, BEST Study  
 159 
 
INSTRUCTIONS FOR RECORDING FOODS, BEVERAGES & SUPPLEMENTS 
 
1. Use brand names and include labels whenever possible. Clean labels can be stapled inside this packet or saved in a bag. 
For example: ¼ cup Bumble Bee tuna, packed in water. 
 
2. Remember to list all additions to foods and beverages, such as cream, sugar, butter, jelly, lemon, salad dressing, artificial 
sweeteners, catsup, etc. Don’t forget ingredients added in food preparation and/or at the table, such as soy sauce, oils, other 
types of fat, and salt. 
 
3. Describe how foods are prepared. For example: ½ cup frozen broccoli, steamed.  
 
4. For multi-vitamin and/or mineral supplements, list the brand, name of the supplement and the amount/dosage in the 
appropriate columns. For example: Brand 400IU vitamin E. If possible, please bring all supplements (vitamin/mineral, herbal 
etc) with you when you come to the clinic.  
 
5. Use measuring cups or spoons whenever possible. For example: 1 tsp. Sugar; 1 ½ cups Campbell’s cream of tomato 
soup. 
 
6. For beverages, indicate if you had ice in the beverage and you may use fluid ounces instead of cups. For example: 12 oz 
Pepsi, no ice.  
 
7. For foods that do not fit in a cup or spoon, use dimensions. For example: 1 corn tortilla, 6 inches across; 1 piece of 
cheddar cheese 3”x2”x1”; 1 banana nut muffin 2”x1”. There is a ruler printed on the back page of this booklet to help with 
measuring foods. 
 
8. For whole pieces of fruit or vegetables, you may use small, medium, or large. Check stickers on fruit for size as well. For 
example: 1 small Granny Smith apple. 
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9. List each food item, and the amount of each item, in mixed dishes. For example: 1cup leaf lettuces, 2 ¼” tomato slices, 
two 2” slices cucumber. 
 
10. For homemade foods, please give us the recipe. When including recipes, be sure to include how much the recipe yields in 
cups and your serving size. For example: Total recipe makes eight 1-cup servings. I had 1 cup.  
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Date:_____________________________                                    Name:___________________________ 
 
TIME Food/Drink Amount Notes 
For 
example: 
8:15 am 
 
Yoplait yogurt, plain, made from skim-milk. 
 
One 8oz container I have included nutrition fact 
panel from box (stapled to 
back page) 
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FOOD LABELS 
Food labels contain a Nutrition Facts panel with product specific information, including serving size, calories, and nutrient 
information. Pay attention to the serving size and number of servings per container. In the sample label, one serving 
of yogurt is one 6 oz container. If the food came in a container with two servings and you ate the entire amount, you would 
double the calories and other nutrients. Pay attention to food labels when keeping your food record.  Attach clean labels to 
this page or feel free to save clean labels in a bag.  
 
             Sample label for yogurt: 
Nutrition Facts 
Serving Size 6 oz (170 g) 
Servings Per Container 1 
Amount Per Serving 
Calories 110                                Calories from Fat  0  
% Daily Value 
Total Fat 0g 
       Saturated Fat 0g 
 Trans Fat 0g 
Cholesterol less than 5mg 
Sodium 90mg 
Potassium 270mg 
Total Carbohydrate 20g 
       Dietary Fiber 0g 
        Sugars 15g 
Protein 6g 
Vitamin A 15% ● Calcium 20% 
Vitamin D 20% ● Phosphorus 
15% Phosphorus 15% 
Percent daily values are based on a 2,000 calorie 
diet. Your daily values may be higher or lower 
depending on your caloric needs. 
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Appendix C: Patient Generated Subjective Global Assessment 
 
 164 
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Appendix D: Quality of Life and Self-Efficacy Questionnaires 
 
                                         Visit (Circle): T1     T2      T3                                                                     Participant ID_____ 
University of Minnesota, Twin Cities 
Department of Food Science and Nutrition 
Part A. Quality of Life 
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the number that best 
applies to you. There are no "right" or "wrong" answers. The information that you provide will remain strictly confidential. 
 Not at All     A Little    Quite a Bit    Very Much 
1. Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a 
suitcase?   1 2 3 4 
2. Do you have any trouble taking a long walk? 1 2 3 4 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4 
5. Do you need help with eating, dressing, washing yourself or using the toilet? 1 2 3 4 
 
DURING THE PAST WEEK 
 
    
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
7. Were you limited in pursuing your hobbies or other leisure time activities? 1 2 3 4 
8. Were you short of breath? 1 2 3 4 
9. Have you had pain? 1 2 3 4 
10. Did you need to rest? 1 2 3 4 
11. Have you had trouble sleeping? 1 2 3 4 
12. Have you felt weak? 1 2 3 4 
13. Have you lacked appetite? 1 2 3 4 
14. Have you felt nauseated? 1 2 3 4 
15. Have you vomited? 1 2 3 4 
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DURING THE PAST WEEK 
 
 
Not at All     
 
A Little    
 
Quite a Bit    
 
Very Much 
16. Have you had diarrhea? 1 2 3 4 
17. Were you tired? 1 2 3 4 
18. Did pain interfere with your daily activities? 1 2 3 4 
19. Have you had difficulty in concentrating on things, like reading a newspaper or watching 
television? 1 2 3 4 
20. Did you feel tense? 1 2 3 4 
21. Did you worry? 1 2 3 4 
22. Did you feel irritable? 1 2 3 4 
23. Did you feel depressed? 1 2 3 4 
24. Have you had difficulty remembering things? 1 2 3 4 
25. Has your physical condition or medical treatment interfered with your family life? 1 2 3 4 
26. Has your physical condition or medical treatment interfered with your social activities? 1 2 3 4 
27. Has your physical condition or medical treatment caused you financial difficulties? 1 2 3 4 
     
For the following questions please circle the number between 1 and 7 that best applies to 
you     
     
28. How would you rate your overall health during the past week?     
      1                     2                     3                  4                      5                 6                   7     
Very poor                                                                                                                   Excellent     
29. How would you rate your overall quality of life during the past week?     
      1                     2                     3                  4                      5                 6                   7     
Very poor                                                                                                                  Excellent     
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Patients sometimes report that they have the following symptoms or problems. Please indicate the extent to which you have 
experienced these symptoms or problems during the past week. Please answer by circling the number that best applies to 
you. 
DURING THE PAST WEEK 
Not at All     A Little    Quite a Bit    
Very 
Much 
30. Have you had pain in your mouth? 1 2 3 4 
31. Have you had pain in your jaw? 1 2 3 4 
32. Have you had soreness in your mouth? 1 2 3 4 
33. Have you had a painful throat? 1 2 3 4 
34. How much difficulty did you experience while eating solid food (like meat/hard bread)? 1 2 3 4 
35. How much difficulty did you experience while eating dry food (like cookies)? 1 2 3 4 
36. How much difficulty did you experience while eating soft food (like soft bread)? 1 2 3 4 
37. Have you had problems swallowing liquids? 1 2 3 4 
38. Have you had problems swallowing pureed food? 1 2 3 4 
39. Have you had problems swallowing solid food? 1 2 3 4 
40. Have you choked when swallowing? 1 2 3 4 
41. Have you had problems with your teeth? 1 2 3 4 
42. Have you had problems opening your mouth wide? 1 2 3 4 
43. Have you had a dry mouth? 1 2 3 4 
44. Have you had sticky saliva? 1 2 3 4 
45. Have you had problems with your sense of smell? 1 2 3 4 
46. Have you had problems with your sense of taste? 1 2 3 4 
47. Have you coughed? 1 2 3 4 
48. Have you been hoarse? 1 2 3 4 
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DURING THE PAST WEEK 
Not at All     A Little    Quite a Bit    
Very 
Much 
49. Have you felt ill? 1 2 3 4 
50. Have you had trouble eating? 1 2 3 4 
51. Have you had trouble eating in front of your family? 1 2 3 4 
52. Have you had trouble eating in front of other people? 1 2 3 4 
53. Have you had trouble enjoying your meals? 1 2 3 4 
54. Have you had trouble talking to other people? 1 2 3 4 
55. Have you had trouble talking on the telephone? 1 2 3 4 
56. Have you had trouble having social contact with your family? 1 2 3 4 
57. Have you had trouble having social contact with friends? 1 2 3 4 
58. Have you had trouble going out in public? 1 2 3 4 
59. Have you had trouble having physical contact with family or friends? 1 2 3 4 
60. Have you felt less interest in sex? 1 2 3 4 
61. Have you felt less sexual enjoyment? 1 2 3 4 
     
DURING THE PAST WEEK No Yes   
62. Have you used pain-killers? 1 2   
63. Have you taken any nutritional supplements (excluding vitamins)? 1 2   
64. Have you used a feeding tube? 1 2   
65. Have you lost weight? 1 2   
66. Have you gained weight? 1 2   
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Part B. Cancer Behavior Inventory-Brief (CBI-B) 
This questionnaire contains many things that a person might do when receiving treatment for cancer. We are interested in your judgment of how 
confident you are that you can accomplish those things. Make sure your ratings accurately reflect your confidence whether or not you have done it in 
the past. So, your ratings reflect your confidence that you can do these things now (or in the near future). Please read each numbered item. Then 
rate that item on how confident you are that you can accomplish that behavior. Circle a number on the scale. If you circle a "1" you would be stating 
that you are not at all confident that you can accomplish that behavior. If you circle a "9" you would be stating that you are totally confident that you 
can accomplish that behavior. Numbers in the middle of the scale indicate that you are moderately confident that you can accomplish that 
behavior.Please rate all items. If you are not sure about an item please rate it as best you can. 
 
NOT AT ALL    
CONFIDENT 
 
MODERATELY  
 CONFIDENT  
 
 
  TOTALLY       
CONFIDENT 
 
1. Maintaining independence 1 2 3 4 5 6 7 8 9 
2. Maintaining a positive attitude 1 2 3 4 5 6 7 8 9 
3. Maintaining a sense of humor 1 2 3 4 5 6 7 8 9 
4. Expressing feelings about cancer 1 2 3 4 5 6 7 8 9 
5. Putting things out of my mind at times                                              1 2 3 4 5 6 7 8 9 
6. Maintaining activities (work, home, hobbies, social)  1 2 3 4 5 6 7 8 9 
7. Trying to be calm throughout treatments and not allowing 
scary thoughts to upset me 
1 2 3 4 5 6 7 8 9 
8. Actively participating in treatment decisions 1 2 3 4 5     6 7 8 9 
9. Asking physicians questions 1 2 3 4 5     6 7 8 9 
10. Seeking social support 1 2 3 4 5 6 7 8 9 
11. Sharing my worries or concerns with others                           1 2 3 4 5 6 7 8 9 
12. Managing nausea and vomiting (whether or not I have had 
these problems in the past) 
1 2 3 4 5 6 7 8 9 
13. Coping with physical challenges 1 2 3 4 5 6 7 8 9 
14. Trying to be calm while waiting at least one hour for my 
appointment 
1 2 3 4 5 6 7 8 9 
 
